US20130225523A1

US20130225523A1 - Glycodendrimers of polypropyletherimine

Info

Publication number: US20130225523A1
Application number: US13/818,557
Authority: US
Inventors: Sunil Shaunak; Ian Alfred Teo
Original assignee: Imperial Innovations Ltd
Current assignee: Ip2ipo Innovations Ltd
Priority date: 2010-08-24
Filing date: 2011-08-22
Publication date: 2013-08-29
Also published as: EP2609105A1; US20150126468A1; AU2011294888B2; CN103154012A; AU2011294888A1; CN103154012B; CN103180333A; WO2012025744A1; BR112013004275A2; US9453040B2; BR112013007492A2; WO2012025745A1; NZ607000A; EP2609105B1

Abstract

A glycodendrimer comprising: a) a non-toxic dendrimer polypropyletherimine core supporting 16 terminal carboxylic acid groups, and b) conjugated to said core 2, 3, 4 or 5 glucosamine molecules, wherein each glucosamine is linked directly through a zero length amide bond with a residue of a terminal carboxylic acid group. The invention also extends to defined populations comprising said glycodendrimer molecules, pharmaceutical compositions comprising said molecules or populations, process for preparing the molecules and formulations, and therapeutic uses of the molecules, populations and compositions.

Description

The present application claims priority from U.S. provisional application 61/344,571 filed 24 Aug. 2010 and GB application number 1109292.1 filed 2 Jun. 2011 both of which are incorporated herein by reference.
The present disclosure relates to glycodendrimers containing a polypropyletherimine core, pharmaceutical formulations comprising same, use of each thereof in treatment, particularly in the treatment of conditions mediated by pro-inflammatory cytokines, such as Interleukin-6 and Interleukin-8 The disclosure further relates to processes for the production of the glycodendrimers, and use of polypropyletherimine cores for preparation of said glycodendrimers.

BACKGROUND

In 2009, Park et al defined the structural basis of the recognition of LPS by TLR4-MD2 [1,2].
In brief, MD2 has a hydrophobic pocket that is lined by a charged, hydrophilic entrance. Lipid A (which consists of two phosphorylated glucosamine molecules linked together via an ester bond) binds to the entrance of this pocket. Its lipid chains then enter MD2's hydrophobic pocket. The TLR4-MD2-LPS complex undergoes a conformational change and TLR4 dimerizes. Intracellular signalling follows.
The importance of the saccharide portions of LPS and of electrostatic interactions between LPS and MD2 have recently been reinforced [3,4].
The most relevant residue is thought to be Tyr102, followed by Lys91, Arg96, Arg106, Asn114 and Ser118. These residues and/or residues in their very close proximity had already been identified as having an important role in the recognition of LPS by MD2 [1,3,4].
Bacterial infections and surgical tissue injury trigger the same cell surface receptor-ligand interactions that are based upon TLR4 immuno-modulation. This does not involve a single receptor-ligand interaction. Rather, these pro-inflammatory cytokine responses are mediated by polyvalent receptor-ligand interactions between bacterially derived lipopolysaccharide (LPS) and/or surgically derived hyaluronan fragments and the cell surface TLR4 receptor [5]. The binding affinity of these ligands for this receptor increases exponentially as the number of receptor-ligand interactions increases. Therefore, it is desirable to adapt the concept of polyvalency to novel biomaterial design by creating new biomaterials that can interact with and modulate tissue injury pathways.
As polyvalency requires multiple and co-operative receptor-ligand interactions, pharmacological intervention will also require new medicines that are based upon molecules that are also capable of multiple and co-operative interactions. This has already been achieved with protein-based medicines, which interact with multiple cell surface receptors with high affinity. For many years the aim has been to achieve analogous co-operative interactions with synthetic macromolecules. However, it has been found that in biological systems, the use of linear polymers has been much less successful than anticipated. Attempts to use linear polymers have been impeded by:—(1) the structural heterogeneity of the macromolecules used; (2) an inability to control their size and molecular weight characteristics; and (3) the toxic side effects of activating complement and coagulation triggered pathways.
In addition, in the case of linear polymers displaying saccharides, they have a tendency to self-associate and to form micelles because of the amphiphilic characteristics of many polymer-saccharide combinations. In the case of polysaccharides, their structural heterogeneity and the complex nature of the chemistry involved in their preparation has impeded the manufacturing scalability and reproducible synthesis of defined oligosaccharide-like molecules with the appropriate biological properties. In general, many synthetic steps are required, and the polar nature of the chemical intermediates and products make them difficult to purify. These compounds are also difficult to handle because they tend to be hygroscopic syrups, chemically labile, susceptible to rapid microbial degradation, and difficult to process into medicines. These fundamental problems have impaired the scale up manufacture of saccharide based macromolecules for pharmaceutical use.
WO 03/089010 disclosed certain glycodendrimers based on the PAMAM core. Generation three PAMAM dendrimers conjugated to glucosamine or glucosamine sulphate to form a 3.5 generation dendrimer have been extensively studied. These molecules have been shown to have very interesting biological activity and low toxicity, and in particular have significant anti-cytokine and anti-chemokine properties.
However, these compounds have not been progressed as pharmaceutical products and have never been dosed to a human because, to date, no way has been identified to commercially and viably manufacture them to a level of “purity” that is suitable for administration to a human. What is more many of the so called impurities are very closely related chemical species to the desired species and thus separation of the different entities is very difficult and may not be possible using currently available chromatography and/or filtration based techniques.
Whilst not wishing to be bound by theory it is now believed by the present inventors that the chemistry on which PAMAM glycodendrimers is based is inherently incompatible with providing a molecule suitable for pharmaceutical use.
Nevertheless PAMAM glycodendrimers are special molecules because of their biological activity. Whilst many cores exist from which dendrimers can be made it seems that glycodendrimers made from alternative cores do not possess the requisite biological properties.
The present inventors believe that, surprisingly, the glycodendrimers described herein are likely to provide biological properties to render them suitable for pharmacological intervention and additionally that the chemistry on which the molecules according to the invention are based is suitable for providing a molecule which can ultimately be used as a pharmaceutical product.

SUMMARY OF THE INVENTION

Thus there is provided a glycodendrimer comprising:
a) a non-toxic dendrimer polypropyletherimine core supporting 16 terminal carboxylic acid groups, and
b) conjungated to said core 2, 3, 4 or 5 glucosamine molecules,
wherein each glucosamine is linked directly through a zero length amide bond with a residue of a terminal carboxylic acid group.

DETAILED DESCRIPTION OF THE INVENTION

Dendrimers are a class of polymeric compounds that can be distinguished from conventional linear polymers by their highly branched, circular and symmetrical architecture.
The first dendrimers were made by divergent synthesis approaches by Vogtle in 1978, Denkewalter at Allied Corporation in 1981, Donald Tomalia at Dow Chemical in 1983 and in 1985 and by Newkome in 1985. In 1990, a convergent synthetic approach was introduced by Jean Fréchet. Dendrimer popularity then greatly increased, resulting in more than 5,000 scientific papers and patents by 2005 [6].
Divergent synthesis is essentially where the molecules are built up in layers from the centre outwards. The reference to generations is in essence a reference to the number of layering steps in the synthesis to produce the dendrimer. Thus in the divergent approach, the dendrimer is grown outwards from the core, typically there is a doubling of the number of reactive functionalities with each new “generation”. However, care needs to be taken with the terminology, generation, because different starting materials require different techniques of synthesis, which can mean that a dendrimer of a certain “generation” made from one starting material may, in some ways, not necessarily be directly comparable to a dendrimer prepared from a different starting material, even though nominally they are given the same numerical generation. The term generation does not equate to absolute physical dimensions of the dendrimer.
In contrast, convergent synthesis is where the molecules are built in fragments and assembled as the last step or at a late stage of synthesis. Thus, the convergent growth method involves the synthesis of dendritic wedges possessing carbohydrates as one of the structural components, followed by the linking of these wedges to further components that provide branching, and then, finally, the attachment of these dendrons to the core component to obtain the desired dendrimer. The adoption of this convergent synthesis protocol typically results in larger quantities of the saccharide being displayed on the surface of the dendrimer in particular it may result in a complete saccharide capping on the dendrimer when the final dendrimer is assembled. Dendrimers prepared convergently are not assigned a generation.
Advantageously, dendrimers have a molecular structure that can be much more precisely defined than is possible for linear polymers [6,7].
As mentioned above, different starting materials can be used to generate the core. Dendrimers based on polyamidoamine (PAMAM) have been extensively studied. PAMAM dendrimers are prepared by divergent synthesis. Detailed reviews of divergently synthesised anionic carboxylic acid terminated PAMAM dendrimers can be found in WO 03/089010 and [8].
PAMAM dendrimers are formed by the incremental addition of branched layers called generations onto a core. Typically, they are available in whole generations which are amine terminated, and half-generations which are carboxylic acid terminated. The generation of a dendrimer is therefore representative of both its size (measured as its diameter in angstroms) and its molecular weight [9] in relative terms.
Divergent dendrimers can also be synthesised from polypropyleneimine (PPI), polylysine, triazine and polypropyletherimine A detailed review in 2010 of the current field of divergently synthesised dendrimers and their applications can be found in [10]. There has been some evidence to suggest that dendrimers which terminate in free carboxylic acids, as opposed to those terminating in amine groups, have improved toxicological profiles [11].
Dendrimers have been applied to a number of fields. In the pharmaceutical field they have been investigated as drug carriers and in diagnostic applications. Very rarely have the dendrimers been considered therapeutic entities in their own right, partly because of their size and complex nature.
In the application of dendrimers as a drug carrier or as a diagnostic tool the field seems to have been obsessed with producing larger and larger dendrimers. There are many synthetic chemistry papers on the matter. However, it should be noted that it has been repeatedly demonstrated in the literature that high valency (in these large molecules) does not correspond with high biological affinity. In fact, the precise nature of the underlying scaffold is as important as the number of copies of saccharide ligand per molecule for molecules that are biologically active [13]. That is to say the core is not simply an inert support for the amino sugar molecule.
WO 03/089010 discloses a generation 3.5 PAMAM dendrimer (64 terminal carboxylic acids) with a partially glycosylated surface which has immuno-modulatory properties. About 15% or less of the surface terminal carboxylic acids are linked to glucosamine by a zero length amide bond. In 2004, Shaunak showed that this dedndrimer blocked pro-inflammatory cytokine responses [8,14] including inhibited the release of the pro-inflammatory cytokines TNF-alpha, IL-1 beta and IL-6 from primary human monocytes, macrophages and dendritic cells by highly purified LPS.
Whilst this PAMAM glycodendrimer molecule has some interesting in vitro and in vivo biological activity, including the prevention of excessive scarring in animal models, this molecule has not been progressed as a therapeutic agent (FIG. 1) because of the inability to make the molecule in a suitable form for use as a pharmaceutical.
Our analysis of the difference between the biologically active glycodendrimers and the biological inactive glycodendrimers leads us to believe that the interaction with specific amino acids residues at the entrance to the cavity of MD2 is important for the biological activity.
We also believe that the hydrophilic entrance of the pocket on MD2 (to which Lipid A binds) is blocked by the glycodendrimer according to the present disclosure and in particular the dendrimer glucosamine This prevents TLR4 dimerization and signalling events.
Our studies have shown that the biologically active partially glycosylated dendrimer shows the largest number and the strongest interactions with several of the residues lining the entrance to MD2's pocket. Several of these residues are also important for the binding of LPS to MD2. The residues with the highest normalized interaction values were Lys91, Tyr102, Arg106, Asn114 and Ser118. Several other residues, with lower interaction values, also contributed significantly to the co-operative binding of the partially glycosylated dendrimer to human MD2; they were Arg96, Ser98, Lys109, Thr112 and Thr116. Thus in one embodiment the dendrimers of the present disclosure interact with one or more (for example 1, 2, 3, 4 or 5) residues selected from Lys91, Tyr102, Arg106, Asn114 and Ser118.
Interact as employed herein refers to non-covalent bonding, for example hydrogen bonds, ionic bonds, van der Waals forces and/or hydrophobic interactions.
In one embodiment the dendrimer of the present disclosure interacts with Lys91. In one embodiment the dendrimer of the present disclosure interacts with Tyr 102. In one embodiment the dendrimer of the present disclosure interacts with Arg106. In one embodiment the dendrimer of the present disclosure interacts with Asn114. In one embodiment the dendrimer of the present disclosure interacts with Ser118. In one embodiment the dendrimer of the present disclosure interacts with: Lys91 and Tyr102; Lys91 and Arg106; Lys91 and Asn114; Lys91 and Ser118; Tyr102 and Arg106; Tyr102 and Asn114; Tyr102 and Ser118; Arg106 and Asn114; Arg106 and Ser118, or Asn114 and Ser118.
In one or more embodiments the dendrimer of the disclosure also has at least one interaction (for example 2, 3, 4 or 5) with a residue selected from Arg96, Ser98, Lys109, Thr112 and Thr116.
In addition, the affinity of a partially glycosylated dendrimer for human MD2 was demonstrated by the increased number of close contacts (i.e., 1.3 Å) between these two molecules that involved both the glucosamine molecules and several of the dendrimer's peripheral carboxylic acid branches. These electrostatic interactions occluded the entrance to human MD2's hydrophobic pocket and are thought to blocked access of the lipid chains of LPS.
It is hypothesised that the biological activity of the dendrimer surface results from the presence of both the amino sugar (or sulfate thereof) and the free peripheral carboxylic acids that are from the core dendrimer.
Advantageously partially glycosylated dendrimers, according to the present disclosure are both flexible and dynamic, and have a hydrophilic periphery, this means that conformational changes could induce shape complementarity. Thus the interaction of the glycodendrimer according to the present disclosure with the biological target, may induce “conformational changes” in the molecule. This is thought to enable the dendrimer's surface saccharides such as glucosamine molecules to block the entrance of human MD2's pocket.
Additional co-operative electrostatic interactions with some of the dendrimer's free carboxylic acid branches follow. Collectively, these interactions as thought to block the entry of the lipid chains of LPS into human MD2's pocket, and also prevent TLR4-MD2-LPS cell surface complex formation. The biologically important outcome is that the pro-inflammatory cytokine cascade is not initiated.
Thus in one embodiment the dendrimer according to the present disclosure has a close interaction with one or more of said amino acid residues in the target, for example those listed above. Close as employed herein is intended to refer to an interaction of 2 Å or less such as 1.5 Å or less, in particular 1.3 Å.
Taken together, the results of our modelling studies and our biological studies suggest that the interaction of the G3.5 partially glycosylated PAMAM dendrimer (and more than likely the glycodendrimers according to the invention) with human MD2 is specific, and that a dendritic architecture is important for this molecule's biological activity [15,16,17,18, 18a]. Our results also suggest that at least two glucosamine molecules, linked via the arms of a dendrimer, are required to bind to several of the exposed and charged amino acids that line the entrance of the cavity on MD2. Thus the glycodendrimers of the present disclosure will generally comprise at least 2 glucosamine molecules (glucosamines).
It is thought that electrostatic interactions over a 20 Angstrom range are responsible for this interaction between dendrimer for example dendrimer glucosamine and MD2 rather than hydrogen bond interactions (which can only occur over a distance of 4 Angstroms).
It is hypothesised that the optimum separation of the two sugar moieties such as the two glucosamine residues for this high affinity binding is probably 10 Å. The binding of dendrimer, for example dendrimer glucosamine to the hydrophilic entrance of the pocket on MD2 almost completely occludes the entrance to the pocket in MD2; it also induces conformational changes in MD2 itself that make it very difficult for LPS to bind to the protein as an effective agonist. Advantageously this reduces pro-inflammatory cytokine production. This important new mechanistic observation shows that dendrimer aminosaccharides—without any lipid chains or phosphate groups attached to the dendrimer—can act as partial antagonists of the binding of LPS to the charged, hydrophilic entrance of the hydrophobic pocket on MD2.
Whilst not wishing to be bound by theory it is thought that the surface properties (outer arm flexibility and charge distribution) and size of the molecule are vital to the biological activity, in particular that a combination of the amino sugar and free carboxylic acids and for example the cluster density such as the zero length amide bond formed are required on a suitably sized scaffold to block the target receptor and generate the therapeutic results. The hydrophilic surface of the glycodendrimer also has an important role to play.
Compounds able to produce co-operative effects are very important in modulating biological control mechanisms in the immune system. What is more they are seldom realised in purely synthetic molecules. The dendrimers of the present disclosure are suitable for producing co-operative effects in vitro and in vivo
Whilst the data generated from the generation 3.5 anionic carboxylic acid terminated PAMAM dendrimer molecule has been very promising and exciting, one reason for its lack of progression is that despite repeated attempts by many workers in the field, to date, it has not been possible to prepare the molecule as a “monodispersion”, in essence a characterisable population of molecules that can be reproducibly prepared to the satisfaction of the drug regulators. To date, no method is available for generating a PAMAM dendrimer as a charactarisable population that can reproducibly prepared to the satisfaction of drug regulators. One may say that the chemistry is inherently flawed in that it is not possible to prevent side reactions occurring during the synthesis of this molecule. The intrinsic problems are caused by incomplete reactions, and cyclization reactions with PAMAM chemistry, which means that there will always be a significant degree of structural heterogeneity to the final PAMAM product.
Thus the inventors have searched for a replacement molecule which shares the characteristics of the generation 3.5 PAMAM dendrimer molecule. However, it turns out that the surface characteristics, size, flexibility and hydrophilicity that provides the desirable biological profiles are not so easy to replicate.
The inventors have now identified a very limited number of glycodendrimers with the desirable biological properties, and with a core based on different chemistry which, with care, can be used to make a molecule that has the purity and the reproducibility of scale up manufacture and will meet the degree of analytical chemical characterisation required of a pharmaceutical drug, for example to generate a monodispersion that is substantially a single chemical entity.
The core is based on polypropyletherimine and surprisingly the glycodendrimers made employing this core seem to at least share the advantageous biological properties of the PAMAM glycodendrimer and may, in one or more areas, show improvements over the PAMAM glycodendrimer.
The term “monodispersion” is used as per the meaning generally understood in the field of dendrimer chemistry. This means that the dendrimer has a narrow molecular weight distribution in which one particular species of a defined molecular weight is predominantly present. More specifically, the one particular species is present at 90% or more, for example 91, 92, 93, 94, 95, 96, 97, 98% or more.
In one embodiment the glycodendrimer of the present invention is a mixture of a small number of well defined chemical entities which are innocuous or substantially similar to the main dendrimer species and for example have similar biological activity.
Thus in one embodiment the molecules of the disclosure will be provided as a population of molecules. The population may comprise a number of discrete molecules some of which may contain more or less than two glucosamines Generally the number of molecules with less than two glucosamines is low, for example less than 3%, such as 2%, 1% or less, in particular 0.5% or 0.1% w/w. In one embodiment the total number of molecules with more than 4 glucosamines is low for example less than 3%, such as 2%, 1% or less, in particular 0.5% or 0.1% w/w. In one embodiment the number of molecules with 3 or 4 glucosamines is 50% w/w or less, for example 40%, 30%, 20%, 10% or 5% w/w or less.
Innocuous in the context of the present specification is intended to refer to an impurity that causes no deleterious effects and is essentially harmless in the biological context. Deleterious effects may, for example, relate to tissue toxicity or catalysis or degradation or any other property that could be considered a disadvantage for a medicine.
Substantially similar as employed herein is intended to refer to where the molecule comprises the same components as the desired species but they are present in a different ratio, for example substantially similar will generally refer to a glycodendrimer comprising the same core and sugars but the number of carboxylic acids on the core and/or the number or of sugars conjugated to the core is different to that which is desired.
In one embodiment the dendrimer core is prepared divergently and thus the resulting dendrimer can be assigned a generation. In one embodiment the generation of the core dendrimer is 3.
Dendrimer core as employed herein is intended to refer to the branched dendrimer polymer before the surface is modified by the conjugation of the glucosamine thereto. Generally, if the final core is being considered then it will terminate in free carboxylic acids. However, if the core is at an intermediate stage it may terminate with a functional group other than a carboxylic acid.
Terminal carboxylic acid group as employed herein is intended to refer to a free carboxylic acid group —C(O)OH, located at the end of one surface branch of the dendrimer and any carboxylic acid residues.
Residue of a terminal carboxylic acid as employed herein is intended to refer to a portion of the terminal carboxylic acid left after a chemical reaction with another entity, such as the amino sugar for example —C(O)—.
Free carboxylic acid group is intended to refer to the unreacted (unconjugated carboxylic acid) —C(O)OH.
Glycodendrimer as employed herein is intended to refer to the entity resulting from conjugating the glucosamine to some of the terminal carboxylic acids on the dendrimer core.
The glucosamine is linked to the dendrimer core by an amide bond formed by a nitrogen in the glucosamine with a carbonyl from a terminal carboxylic acid group. This is a direct amide bond, also referred to as a zero length amide bond.
For a given population of molecules the numbers of carboxylic acids present may be calculated as an average over the whole population.
In one embodiment the population is defined in that it will not include molecules with carboxylic acids below a defined lower threshold and above a defined upper threshold, for example where 16 carboxylic acid contained molecules are required the lower limit may be 12 and the upper limit may be 20 or even 18.
In one embodiment a glycodendrimer comprises a corresponding number of terminal carboxylic acids and carboxylic acid residues to the total number of free carboxylic acids in the starting (before conjution). That is to say the combined number of terminal carboxylic acids and carboxylic acid residues corresponds to the number of carboxylic acids in the starting core. In the glycodendrimer molecules of the present disclosure there is at least one and generally more than one free carboxylic acid, for example where the number of free carboxylic acids =X−Y, wherein X is a number in the range 12 to 20 (and corresponds to the number of carboxylic acids of the dendrimer core) and Y is a number in the range 1 to 5 (and corresponds the number of surface conjugated sugar molecules).
In one embodiment the number of free carboxylic acids after conjugation in a given molecule is 11, 12, 13 or 14, for example 14. The invention also extends to a population of glycodendrimers comprising molecules with 11, 12, 13 or 14 free carboxylic acids. These free carboxylic acids are likely to have a role to play in facilitating the enhanced polyvalent binding of the glycodendrimer to the target receptor and hence are relevant to the biological activity of the molecules.
The glycodendrimers according to the disclosure may be provided as a discrete population of the molecules that this characterisable.
Advantageously, carboxylic acid terminated anionic polypropyletherimine dendrimers have a remarkable lack of toxicity in vitro compared to cationic polypropyletherimine dendrimers [19]. This inherent toxicity of higher generation cationic dendrimers means that they are unlikely to be suitable or safe for repeated intravenous administration as a pharmaceutical drug in man [11]. Thus the glycodendrimers of the present disclosure are believed to have low toxicity, which renders them suitable for use as a pharmaceutical.
In one embodiment 2, 3, 4 or 5 glucosamines are conjugated to the dendrimer core, for example a core containing on average 16 carboxylic acids, for example 2, 3, or 4, such as 2 or 3. In one embodiment 2 glucosamines are conjugated to the dendrimer core.
In one embodiment there is provided a population of molecules with on average 2, 3, 4 or 5 glucosamines are conjugated to the dendrimer core, for example a core containing on average 16 carboxylic acids, for example 2, 3, or 4, such as 2 or 3.
In one embodiment on average 2, 3, 4, or 5 glucosamines are conjugated to the dendrimer core. This population may comprise molecules with between 1 and 8 glucosamines conjugated thereto. However, the latter will generally be in a minority, for example less than 10% w/w or 5% w/w or less, such as 3%, 2% or 1% or less.
In one embodiment the main species of glycodendrimer comprises 2 glucosamines but the population may, for example also comprise entities with 1, 3, 4 and/or 5 glucosamines, such as 1 or 3.
Even in a glycodendrimer population of molecules with the same number of glucosamines conjugated thereto the molecules may be present as region-isomers. That is to say the relative positions of the glucosamines in particular glycodendrimers may vary. That is to say the spatial arrangement of the glucosamines may differ in one molecule compared to another molecule in the population.
In one embodiment the number of region-isomers of the main glycodendrimer species is minimised, in particular, for a given population of glycodendrimers with the same number of glucosamines conjugated thereto at least 50% of said population will be the desired region-isomer, in particular 75% will be the desired region-isomer.
The region-isomer distribution may be influenced to provide the desired outcome by optimising the synthetic chemistry conditions during conjugation.
In one embodiment 33% or less of the dendrimers carboxylic acids are conjugated to a glucosamine, for example 29%, 28,%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18,%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less of the dendrimers carboxylic acids are conjugated, such as 18.75 or 12.5%.
In one embodiment the number of conjugated carboxylic acids is in the range 3% to 14%, such as 6% to 13%, in particular 12.5%.
However the current inventors believe that at least two glucosamines are required in each molecule to effectively block the target receptor.
Furthermore in one aspect there is provided a highly optimized glycodendrimer comprising 2 glucosamines and 14 remaining free carboxylic acids. In one embodiment the dendrimer is a population of dendrimers where the later entity is the major component, for example as a monodispersion.
This molecule (i.e., generation 3 anionic carboxylic acid terminated polypropyletherimine dendrimer glucosamine) is physically smaller than the generation 3.5 PAMAM dendrimer glucosamine previously described in the art. The generation 3.5 PAMAM dendrimer had 64 terminal carboxylic acids in the core.
Surprisingly, this small polypropyletherimine dendrimer has only 16 terminal carboxylic acids in the core. At the same concentration (on a mg/ml basis), it is believed that the use of polypropyletherimine cores for preparation of said glycodendrimers can reduce some pro-inflammatory cytokines to an equal or a greater extent than the generation G3.5 PAMAM dendrimer glucosamine as summarised in Table 1 below.

TABLE 1

Summary table of results from several of the figures shown.
It quantifies the fold reduction in pro-inflammatory cytokines
with G3 polypropyletherimine dendrimer glucosamine when
compared to G3.5 PAMAM dendrimer glucosamine. The
100% control = stimulation of cytokine release from cells
that were stimulated with 25 ng/ml LPS.

	Drug concentration - tested
	in human cells (μg/ml)

Cytokine	200	100	50	25	12.5

TNF-α
G3 polypropyletherimine	nd	390	570	807	477
dendrimer glucosamine
G3.5 PAMAM	112	84	7	2	nd
dendrimer glucosamine
IL-8
G3 polypropyletherimine	nd	165	192	288	17
dendrimer glucosamine
G3.5 PAMAM	9	10	2	1	nd
dendrimer glucosamine
MIP-1β
G3 polypropyletherimine	nd	165	193	288	17
dendrimer glucosamine
G3.5 PAMAM	54	53	6	2	nd
dendrimer glucosamine
IL-6
G3 polypropyletherimine	nd	75	40	40	2
dendrimer glucosamine
G3.5 PAMAM	835	910	178	5	nd
dendrimer glucosamine

(nd = not done)

This small and optimized generation 3 (G3) polypropyletherimine dendrimer glucosamine may be particularly useful from a pharmaceutical perspective because it will be more cost effective to manufacture in respect of the starting materials employed to manufacture the same, and the ease of execution of the chemical steps required to manufacture the final medicinal product.
The dendrimer core is a polypropyletherimine core. Usually this is based on units of 3-amino-propa-1-ol. Depending on how the dendrimer is synthesised, there can be an oxygen atom at the centre of the core or a nitrogen atom at the centre of the core. For details of polypropyletherimine dendrimers with nitrogen at the core see [20]. For details of polypropyletherimine dendrimers with oxygen at the core see the following papers [19,21,22].
In one embodiment the core is a polypropyletherimine based on 3 -amino-propan-1 -ol. These dendrimers can have an oxygen atom or a nitrogen atom at the very core of the molecule.
In one embodiment the dendrimer has an oxygen atom at the very core of the molecule.
In one embodiment the dendrimer has a nitrogen atom at the very core of the molecule.
The glycodendrimers herein are referred to as a polypropyletherimine glycodendrimers.
These new anionic polypropyletherimine glycodendrimers are thought to bind to the cell surface TLR4 receptor on monocytes and macrophages and dendritic cells to reduce the production of the pro-inflammatory cytokines IL-6, TNF-alpha, IL-8 and/or IL-1 beta in response to LPS or hyaluronan fragments.
Surprisingly, these dendrimers cores, when used, provide the correct combination of features to support a 30% or less such as a 20% or less loading of glucosamine and to provide the biological activity. It is especially surprising that the small generation polypropyletherimine glycodendrimers have advantageous biological activity.
In one embodiment there is provided a glycodendrimer wherein the glycodendrimer is a generational dendrimer. In one embodiment there is provided a glycodendrimer wherein the dendrimer core is a generation 3.
In one embodiment there is provided a generation 3 anionic carboxylic acid terminated (i.e., 16 peripheral carboxylic acid groups) polypropyletherimine glycodendrimer (such as glucosamine glycodendrimer) with a 12.5% surface loading of glucosamine (i.e. 2 glucosamine molecules) with a zero length amide bond between the dendrimer core and the glucosamine. In one embodiment the two glucosamine molecules are present on opposite sides of the surface of the dendrimer as shown in FIG. 4 (that is to say spatially separated to be the maximum distance apart).
In one embodiment there is provided a generation 3 anionic carboxylic acid terminated (i.e., 16 peripheral carboxylic acid groups) polypropyletherimine glucosamine glycodendrimer with a 18.75% surface loading of sugar such as glucosamine (i.e. 3 glucosamine molecules) with a zero length amide bond between the dendrimer core and the glucosamine.
Thus in one embodiment there is provided a generation 3 anionic carboxylic acid terminated (i.e., 16 peripheral carboxylic acid groups) polypropyletherimine glycodendrimer (such as glucosamine glycodendrimer) with a 25% surface loading of glucosamine (i.e. 4 glucosamine molecules) with a zero length amide bond between the dendrimer core and the sugar such as glucosamine.
Thus in one embodiment there is provided a generation 3 anionic carboxylic acid terminated (i.e., 16 peripheral carboxylic acid groups) polypropyletherimine glycodendrimer (such as glucosamine glycodendrimer) with a 31.25% surface loading of sugar such as glucosamine (i.e. 5 sugar molecules such as glucosamine molecules) with a zero length amide bond between the dendrimer core and the sugar such as glucosamine
The invention also provides a population of glycodendrimers wherein the average properties of the population are as defined herein. In one embodiment there is provided a composition comprising a population of generation 3 anionic carboxylic acid termination polypropyletherimine glycodendrimer molecules bearing 2 or 3 glucosamines.
In one embodiment there is provided a composition comprising a mixture of generation 3 anionic carboxylic acid termination polypropyletherimine glycodendrimer molecules bearing 3 or 4 sugars, such as 3 or 4 glucosamines.
The ratio of molecules bearing different numbers of sugar molecules, for example molecules bearing 2 glucosamines and molecules bearing 3 glucosamines (or the molecules with 3 glucosamines and molecules with 4 glucosamines) in the mixture is in the range 1 to 99%: 99 to 1% respectively and may for example be 50:50, 75:25 or 25:75 etc.
In one embodiment there is provided a composition comprising a mixture of generation 3 anionic carboxylic acid termination polypropyletherimine glycodendrimer molecules bearing 4 or 5 sugars, such as 4 or 5 glucosamines.
In one embodiment the glycodendrimer according to the disclosure has 13 or 14 free carboxylic acids, such as 14. In one embodiment the glycodendrimer according to the disclosure has 13 free carboxylic acids. In one embodiment the glycodendrimer according to the disclosure has 12 free carboxylic acids. In one embodiment the glycodendrimer according to the disclosure has 11 free carboxylic acids.
Opposite sides of the molecule as employed herein is intended to refer to diametrically opposed glucosamines, or a similarly thermodynamically and sterically favourable conformation. It may be that the divergent approach to the synthesis of dendrimer glucosamine leads to the favourable addition of 2 glucosamine molecules to two of the 16 carboxylic acid groups of a generation 3 anionic carboxylic acid terminated polypropyletherimine dendrimer. Typically, we believe the two glucosamine molecules are situated at diametrically opposite ends of the surface of the dendrimer [15,16,17].
This is also provided a dendrimer with a ratio of combined terminal carboxylic acids/acid resides to the number of glucosamines conjugated thereto is in the range 8:1 to 6:1, in particular 8:1.
In one embodiment the amino sugars such as glucosamines are evenly spaced on the surface of the dendrimer.
Evenly spaced as employed herein is intended to refer to the fact that the glucosamines are spread across the surface of the dendrimer in a balanced manner and are not clumped together in one or more isolated locations on the surface.
Advantageously, dendrimers are hyperbranched, wherein the ends of each branch define the molecular surface of the dendrimer. Notably, (1) their physico-chemical properties are similar to those of conventional small molecule drugs; (2) they can be modified to exist as zwitterions at physiological pH; and (3) they have a considerable buffering capacity that makes them physico-chemically “similar” to blood proteins (e.g., albumin), and therefore biocompatible. However, unlike proteins, they (1) do not undergo proteolytic degradation in plasma; (2) are not immunogenic; (3) are not toxic after repeated intravenous administration; (4) can be optimized for their circulation time; and (5) show preferential accumulation in tissues containing inflammatory cells compared to healthy tissue at a ratio of 50:1. In addition, the National Cancer Institute's Nanotechnology Characterisation Laboratory recently undertook detailed chemical and toxicological characterization of anionic PAMAM dendrimers and found them to be both stable and biocompatible (see the Nanotechnology Characterisation Laboratory NCI (2006) Dendrimer-based MRI contrast agents website—http.//ncl.cancer.gov/working_technical_reports.asp).
Advantageously, the glycodendrimers of the present disclosure are stable, in that they are suitable for storage under appropriate conditions before use, for example use as a therapeutic agent.
In a further aspect, the present invention provides a pharmaceutical formulation comprising a polypropyletherimine glycodendrimer of the invention and optionally a pharmaceutically acceptable carrier/excipient.
In one embodiment the formulation comprises 10 μg to 1 g of glycodendrimer of the present disclosure.
The compounds and formulations of the invention are suitable for administration parenterally for example intravenously, subcutaneously, intramuscularly, intraperitoneally and intraocularly; orally; topically including by aerosol, for example intranasally, by pulmonary administration, directly to the eye, transdermally (skin) such as via an impregnated plaster or a skin patch, in particular to the surface of the skin transdermal by a slow release preparation; and intramucosally for example by buccal or rectal administration, for example as a rectal enema wherein the compound is formulated in a suitable carrier such as an aqueous carrier.
In one embodiment the formulation is suitable for topical administration.
In one embodiment the formulation is suitable for infusion or direct injection.
In one embodiment the formulation is suitable for oral administration.
Topical administration as employed herein includes administration to orally to the GI tract and colon etc, wherein the compound administered is not absorbed systemically.
In another aspect, the invention provides a pharmaceutical composition comprising, as active ingredient, a compound of the disclosure or a pharmaceutically acceptable derivative thereof in association with a pharmaceutically acceptable excipient, diluent and/or carrier for use in therapy, and in particular, in the treatment of human or animal subjects suffering from a condition susceptible to amelioration by an antimicrobial compound.
An active ingredient as employed herein is intended to refer to a pharmacologically effective ingredient, for example which are therapeutically efficacious. Examples of active ingredients include corticosteroids, for example fluticasone propionate, fluticasone furoate, mometasone furoate, dexamethasone, cortisone, hydrocortisone, betamethasone, prednisolone; non-steriodal anti-inflammatories for example aspirin, ibuprofen, naproxen.
There is further provided by the present disclosure a process of preparing a pharmaceutical composition, which process comprises mixing a compound of the disclosure or a pharmaceutically acceptable derivative thereof, together with a pharmaceutically acceptable excipient, diluent and/or carrier.
The compounds of the disclosure may be formulated for administration in any convenient way for use in human or veterinary medicine and the disclosure therefore includes within its scope pharmaceutical compositions comprising a compound of the disclosure adapted for use in human or veterinary medicine. Such compositions may be presented for use in a conventional manner with the aid of one or more suitable excipients, diluents and/or carriers. Acceptable excipients, diluents and carriers for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro edit. 1985). The choice of pharmaceutical excipient, diluent and/or carrier can be selected with regard to the intended route of administration and standard pharmaceutical practice. The pharmaceutical compositions may comprise as—or in addition to—the excipient, diluent and/or carrier any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilising agent(s).
Preservatives, stabilisers, dyes and even flavouring agents may be provided in the pharmaceutical composition. Examples of preservatives include sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid. Antioxidants and suspending agents may also be used.
For some embodiments, the agents of the present disclosure may also be used in combination with a cyclodextrin. Cyclodextrins are known to form inclusion and non-inclusion complexes with drug molecules. Formation of a drug-cyclodextrin complex may modify the solubility, dissolution rate, bioavailability and/or stability property of a drug molecule. Drug-cyclodextrin complexes are generally useful for most dosage forms and administration routes. As an alternative to direct complexation with the drug the cyclodextrin may be used as an auxiliary additive, e. g. as a carrier, diluent or solubiliser. Alpha-, beta- and gamma-cyclodextrins are most commonly used and suitable examples are described in WO 91/11172, WO 94/02518 and WO 98/55148.
The compounds of the disclosure may be milled using known milling procedures such as wet milling to obtain a particle size appropriate for tablet formation and for other formulation types. Finely divided (nanoparticulate) preparations of the compounds of the invention may be prepared by processes known in the art, for example see International Patent Application No. WO 02/00196.
The routes for administration (delivery) include, but are not limited to, one or more of: oral (e. g. as a dry powder/free flowing particulate formulation, tablet, capsule, or as an ingestible solution or suspension) rectal, buccal, and sublingual. The compositions of the disclosure include those in a form especially formulated for parenteral, oral, buccal, rectal, topical, implant, ophthalmic, nasal or genito-urinary use. In one aspect of the invention, the agents are delivered orally, hence, the agent is in a form that is suitable for oral delivery.
In some instances it may be possible to deliver the compounds of the disclosure by a topical, parenteral (e. g. by an injectable form) or transdermal route, including mucosal (e. g. as a nasal spray or aerosol for inhalation), nasal, gastrointestinal, intraspinal, intraperitoneal, intramuscular, intravenous, intrauterine, intraocular, intradermal, intracranial, intratracheal, intravaginal, intracerebroventricular, intracerebral, subcutaneous, ophthalmic (including intravitreal or intracameral).
There may be different composition/formulation requirements depending on the different delivery systems. By way of example, the pharmaceutical composition of the present disclosure may be formulated to be delivered using a mini-pump or by a mucosal route, for example, as a nasal spray or aerosol for inhalation or ingestable solution, or parenterally in which the composition is formulated in an injectable form, for delivery by, for example, an intravenous, intramuscular or subcutaneous route. Alternatively, the formulation may be designed to be delivered by both routes. Where appropriate, the pharmaceutical compositions can be administered by inhalation, in the form of a suppository or pessary, topically in the form of a lotion, solution, cream, ointment or dusting powder, by use of a skin patch, orally in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs, solutions or suspensions containing flavouring or colouring agents, or they can be injected parenterally, for example intravenously, intramuscularly or subcutaneously.
For buccal or sublingual administration the compositions may be administered in the form of tablets or lozenges which can be formulated in a conventional manner.
For parenteral administration, the compositions may be best used in the form of a sterile aqueous solution which may contain other substances, for example enough salts or monosaccharides to make the solution isotonic with blood.
If a compound of the present disclosure is administered parenterally, then examples of such administration include one or more of: intravenously, intraarterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally, intrasternally, intracranially, intramuscularly for example as a bolus fomulation or subcutaneously administering the agent, and/or by using infusion techniques.
Formulations for parenteral administration may be provided in a lyophilised form for reconstitution with a water of injection or infusion or an isotonic solution, such as glucose.
The compounds of the disclosure can be administered (e. g. orally or topically) in the form of tablets, capsules, ovules, elixirs, solutions or suspensions, which may contain flavouring or colouring agents, for immediate-, delayed-, modified-, sustained-, pulsed- or controlled-release applications.
The compounds of the disclosure may also be presented for human or veterinary use in a form suitable for oral or buccal administration, for example in the form of solutions, gels, syrups, mouth washes or suspensions, or a dry powder for constitution with water or other suitable vehicle before use, optionally with flavouring and colouring agents.
Solid compositions such as tablets, capsules, lozenges, pastilles, pills, boluses, powder, pastes, granules, bullets or premix preparations may also be used. Solid and liquid compositions for oral use may be prepared according to methods well known in the art. Such compositions may also contain one or more pharmaceutically acceptable carriers and excipients which may be in solid or liquid form.
The tablets may contain excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, calcium sulphate, dibasic calcium phosphate and glycine, mannitol, pregelatinised starch, corn starch, potato starch, disintegrants such as sodium starch glycollate, croscarmellose sodium and certain complex silicates, and granulation binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, gelatin and acacia.
Additionally, lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included.
Solid compositions of a similar type may also be employed as fillers in gelatin or HPMC (hydroxypropyl methylcellulose) capsules. Preferred excipients in this regard include microcrystalline cellulose, lactose, calcium carbonate, calcium sulphate, dibasic calcium phosphate and, mannitol, pregelatinised starch, corn starch, potato starch or high molecular weight polyethylene glycols. For aqueous suspensions and/or elixirs, the agent may be combined with various sweetening or flavouring agents, colouring matter or dyes, with emulsifying and/or suspending agents and with diluents such as water, ethanol, propylene glycol and glycerin, and combinations thereof.
Capsules, may be filled with a powder (of medicament alone or as blend with selected filler(s)) or alternatively a liquid, each comprising one or more compounds of the invention and a carrier. Where the capsule is filled with a powder the compounds of the invention and/or the carrier may be milled or micronised to provide material with an appropriate particle size.
Compounds of the disclosure may be coated, for example with an enteric coating when administered orally as a tablet or capsule. The tablet or capsule, as appropriate, may, for example be coated by a thin film such as a EUDRAGIT® film available from Rohm Pharma Polymers, which allows controlled dissolution in the gastrointestinal tract. The films are available as cationic polymers such as EUDRAGIT® E 100 (aminoalkyl methacylate copolymers) or as anionic acrylic polymers such as EUDRAGIT® L (methacrylic acid copolymers) and EUDRAGIT S.
Permeable acrylic polymers such as EUDRAGIT® RL (amino methacrylate copolymer) and EUDRAGIT® RS are also available.
These coating formulations may be prepared as an aqueous dispersion including optional ingredients such as talc, silicone antifoam emulsion, polyethylene glycol. Alternatively the coating formulation may be prepared as an organic polymer solution.
Alternatively, tablets may be coated using OPADRY® (Surelease®) coating systems, available from Colorcon. Aqueous systems generally comprise up to 15% w/w of OPADRY®. Organic solvent systems generally comprise up to 5% w/w of OPADRY®.
The coatings may be prepared by known techniques, for example by: 1. weighing the required quantity of OPADRY® film coating system, 2. weighing the required quantity of water or other solvent(s) into a mixing vessel, 3. with a mixing propeller in the centre of the vessel and as close to the bottom of the vessel as possible, stirring the solvents to form a vortex without drawing air into the liquid, 4. steadily and quickly adding the OPADRY® powder to the vortex, avoiding powder flotation on the liquid surface, 5. increasing the stirrer speed in order to maintain the vortex, if required, and 6. after all the powder ingredients have been added, reducing the mixer speed and continuing mixing for approximately 45 minutes.
Coatings can be applied by known techniques, using tablet coating machines. The thickness of the coating applied is generally in the range 5 to 35 microns such as 10 to 30 microns, more specifically 10 or 20 microns, depending on the required effect.
Alternatively, the tablet or a capsule, as appropriate, may be filled into another capsule (preferably a HPMC capsule such as Capsugel®) to provide either a tablet in capsule or capsule in capsule configuration, which when administered to a patient yields controlled dissolution in the gastrointestinal tract thereby providing a similar effect to an enteric coating.
Thus in one aspect the disclosure provides a solid dose formulation of a compound of invention for example where the formulation has an enteric coating.
In another aspect the disclosure provides a solid dose formulation comprising a protective capsule as outer layer, for example as a tablet in a capsule or a capsule in a capsule. The enteric coating may provide an improved stability profile over uncoated formulations.
The compounds of the disclosure may also be administered orally, in veterinary medicine, in the form of a liquid drench such as a solution, suspension or dispersion of the active ingredient together with a pharmaceutically acceptable carrier or excipient.
The compounds of the invention may also, for example, be formulated as suppositories e.g. containing conventional suppository bases for use in human or veterinary medicine or as pessaries e.g. containing conventional pessary bases.
In one embodiment the formulation is provided as a formulation for topical administration including inhalation.
Suitable inhalable preparations include inhalable powders, metering aerosols containing propellant gases or inhalable solutions free from propellant gases. Inhalable powders according to the disclosure containing the active substance may consist solely of the abovementioned active substances or of a mixture of the abovementioned active substances with physiologically acceptable excipient.
These inhalable powders may include monosaccharides (e.g. glucose or arabinose), disaccharides (e.g. lactose, saccharose, maltose), oligo- and polysaccharides (e.g. dextranes), polyalcohols (e.g. sorbitol, mannitol, xylitol), salts (e.g. sodium chloride, calcium carbonate) or mixtures of these with one another. Mono- or di-saccharides are preferably used, the use of lactose or glucose, particularly but not exclusively in the form of their hydrates.
Particles for deposition in the lung require a particle size less than 10 microns, such as 1-9 microns suitably from 0.1 to 5 μm, particularly preferably from 1 to 5 μm. The particle size of the active (i.e. the compound according to the disclosure) should be in this range. The size of particle of excipients such as lactose may be larger than this range.
The propellant gases which can be used to prepare the inhalable aerosols are known from the prior art. Suitable propellant gases are selected from among hydrocarbons such as n-propane, n-butane or isobutane and halohydrocarbons such as chlorinated and/or fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane. The above-mentioned propellent gases may be used on their own or in mixtures thereof.
Particularly suitable propellant gases are halogenated alkane derivatives selected from among TG11, TG12, TG 134a and TG227. Of the abovementioned halogenated hydrocarbons, TG134a (1,1,1,2-tetrafluoroethane) and TG227 (1,1,1,2,3,3,3-heptafluoro propane) and mixtures thereof are suitable for use in formulations of the present invention.
The propellant-gas-containing inhalable aerosols may also contain other ingredients such as co-solvents, stabilisers, surface-active agents (surfactants), antioxidants, lubricants and means for adjusting the pH. All these ingredients are known in the art.
The propellant-gas-containing inhalable aerosols according to the invention may contain up to 5% by weight of active substance. Aerosols according to the disclosure may contain, for example, 0.002 to 5% by weight, 0.01 to 3% by weight, 0.015 to 2% by weight, 0.1 to 2% by weight, 0.5 to 2% by weight or 0.5 to 1% by weight of active.
The compounds of the disclosure may also be used in combination with other therapeutic agents. The disclosure thus provides, in a further aspect, a combination comprising a compound of the present disclosure or a pharmaceutically acceptable derivative thereof together with a further therapeutic agent. The combination may be provided as a co-formulation or simply packaged together as separate formulations, for simultaneous or sequential delivery.
A list of possible active ingredients that may complement the therapeutic activity of the glycodendrimer according to the present disclosure is given above.
Therapeutic antibodies may also complement the therapeutic activity of the glycodendrimer according to the present disclosure. Examples of therapeutic antibodies include anti-TNF-alpha antibodies, for example etanercept, infliximab, adalimumab, certolizumab pegol, golimumab; Interleukin 1 antibodies, for example anakinra; rituximab; abatacept; and tocilizumab.
It is to be understood that not all of the compounds (or molecules) of the combination need be administered by the same route. Thus, if the therapy comprises more than one active component, then those components may be administered by different routes.
The individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations by any convenient route.
When administration is sequential, either the compound of the disclosure or the second (further) therapeutic agent may be administered first. When administration is simultaneous, the combination may be administered either in the same or a different pharmaceutical composition.
The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above together with a pharmaceutically acceptable carrier or excipient comprise a further aspect of the disclosure.
When combined in the same formulation it will be appreciated that the two compounds must be stable and compatible with each other and the other components of the formulation. When formulated separately they may be provided in any convenient formulation, in such manner as are known for such compounds in the art.
The compositions may contain from 0.01-99% of the active material. For topical administration, for example, the composition will generally contain from 0.01-10%, more preferably 0.01-1% of the active material.
Processes for preparing said pharmaceutical formulations may, for example, be performed under controlled environments, such as controlled humidity conditions.
In one embodiment the pharmaceutical formulation is protected from light, for example is stored in amber bottles or vials, foil wrapped or packaged, such as foil overwrapped or filled into foil blister packs or foil sachets. In one embodiment the pharmaceutical formulation is protection from moisture, for example foil wrapped or packaged, such as foil overwrapped or filled into foil blister packs or foil sachets. In one embodiment the formulation is protected from air/oxygen, for example by storage under nitrogen.
Blister packaging is well known to those skilled in the art, however, in one embodiment the blister is a so-called tropical blister available from amcor or a similar blister available from Alcan. US2006/0283758 incorporated by reference discloses certain blister packs suitable for use with formulations of the invention.
Advantageously appropriately packaged formulations of the present disclosure can be stored at room temperature.
When a compound of the disclosure or a pharmaceutically acceptable derivative thereof is used in combination with a second therapeutic agent active against the same disease state, the dose of each compound may be the same or differ from that employed when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art. It will also be appreciated that the amount of a compound of the disclosure required for use in treatment will vary with the nature of the condition being treated and the age and the condition of the patient and will be ultimately at the discretion of the attendant physician or veterinarian.
Typically, a physician will determine the actual dosage which will be most suitable for an individual subject. The specific dose level and frequency of dosage for any particular individual may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the individual undergoing therapy.
For oral and parenteral administration to humans, the daily dosage level of the agent may be in single or divided doses. For systemic administration the daily dose as employed for adult human treatment will range from 2-100 mg/Kg body weight, preferably 5-60 mg/Kg body weight, which may be administered in 1 to 4 daily doses, for example, depending on the route of administration and the condition of the patient. When the composition comprises dosage units, each unit will preferably contain 100 mg to 1 g of active ingredient. The duration of treatment will be dictated by the rate of response rather than by arbitrary numbers of days. In one embodiment the treatment regime is continued for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or more days.
As described above, the compounds of the present disclosure and composition comprising the same may be employed in the treatment or prophylaxis of humans and/or animals.

Managing Uncontrolled Immunological Trauma in Elective Surgery

Elective surgery causes the release of tissue enzymes that degrade high molecular weight hyaluronan into low molecular weight hyaluronan. The small fragments trigger TLR4 mediated pro-inflammatory responses in a manner that is almost identical to bacterially derived LPS. An excessive pro-inflammatory cytokine release interferes with the normal phases of wound healing. The excessive angiogenesis that accompanies this host innate immune response increases pro-inflammatory monocyte recruitment to the wound site. Scarring is due to a persistent pro-inflammatory response that promotes fibroblast proliferation. Shaunak postulated that early inhibition of an immuno-modulatory pathway and an anti-angiogenic pathway would enable physiological (rather than pathological) repair and regeneration of surgically induced injury without causing scar tissue formation [8].
A rabbit model of glaucoma filtration surgery was chosen because the surgical intervention is precisely defined, and because surgical failure results from an excessive pro-inflammatory response combined with a neo-angiogenic response. When used in combination, PAMAM dendrimer glucosamine and PAMAM dendrimer glucosamine 6-sulfate increased the success rate of glaucoma filtration surgery from 30% to 80% (P=0.029) in this clinically validated rabbit model. Therefore, this combination of dendrimer based drugs safely and synergistically prevented scar tissue formation after surgery. Histological studies showed that the degree of tissue based inflammatory cell infiltration and abnormal collagen formation was minimal [5,18].
It is believed that the glycodendrimers of the present invention also have these properties. Thus there is provided a glycodendrimer of the present disclosure or a combination thereof or a pharmaceutical composition comprising the same for use in treatment or prophylaxis, in particular the treatment or prophylaxis of surgery induced tissues damage or tissue injury or damage that if untreated would lead to scaring and impairment of the original tissue function, for example for the treatment or prevention of scar tissue in eye tissue.

Tissue Damaging Cascades

Both surgical trauma and bacterial infections can lead to severe tissue injury that can be triggered by cell surface TLR4 mediated receptor-ligand interactions. These polyvalent interactions between bacterially derived ligands as well as endogenous hyaluronan fragments can lead to the release of life threatening pro-inflammatory cytokines such as IL-6 and TNF-alpha. As a result, this pathway is tightly regulated in all biological organisms. The checkpoints that initiate as well as arrest this tissue damaging cascade are important because they have the potential of being manipulated with pharmaceutical drugs.
Thus in one embodiment there is provided use of a compound according to the disclosure and compositions comprising the same for the treatment or prophylaxis of scarring, including excessive scarring, particularly after surgery, whether internal to the body or relating to a surface organ of the body; e.g. such as the skin or a mucosal surface or a surface related to the eye.

The Inflammatory Response Associated With Bacterial Infections

Fundamental to innate immunity are the pattern recognition receptors (TLRs) that recognize pathogen associated molecular patterns. They allow the immune system to distinguish self structures from pathogen associated non self molecules. They are the first line of host defense against invading pathogens [23].
TLR4 on macrophages and dendritic cells is the key cell surface receptor. Antigen mediated triggering leads to cytokine expression, dendritic cell maturation, and adaptive immune responses.
Only a very short stimulation of TLR4 is required to lead to dendritic cell maturation and T cell stimulation. This contrasts with the prolonged and sustained stimulation of TLR4 that is required for the induction of pro-inflammatory cytokines such as TNF-α and IL-6. Distinct thresholds therefore exist within the TLR4-MD2-LPS complex (at the level of the cell surface) for inducing the expression of CD markers of cellular differentiation compared to the release of cytokines [1]. This unique nature of TLR4 compared to all other TLR receptors has only been recently recognized [24].
Thus in one aspect there is provided use of compounds of the present disclosure and compositions comprising same for the treatment or prophylaxis of inflammatory responses or inflammatory disease, for example a response mediated by increased levels of one or more cytokines selected from the group comprising IL-6, TNF-alpha, IL-8, IL-1 beta and MIP-1 beta. In one embodiment the inflammatory mechanism is in response, for example in response to LPS and/or hyaluronan fragments that bind to the cell surface receptor TLR4 and/or to bacterial infection, for example in the lining of the gut.
In one embodiment there is provided glycodendrimer, population or formulation according to the present disclosure for use in the treatment or prophylaxis of a disease that is associated with an excessive pro-inflammatory cytokine response by the host/patient.
In one embodiment there is provided a glycodendrimer or population according to the present disclosure or a composition comprising the same for the treatment or prophylaxis of inflammation associated with Gram negative infections, for example Gram negative infection is associated with diarrhoea, such as those caused by Shigella sp. and Salmonella sp.
In one embodiment there is provided a glycodendrimer, population or formulation according to the present disclosure wherein the infection is caused by Escherichia coli, Klebsiella aeruginosa, Staphylococcus aureus, Escherichia faecalis, Pseudomonas aerugenosa, and/or any other infectious organism.
In one embodiment there is provided a glycodendrimer according to the present disclosure or a composition comprising the same for the treatment or prophylaxis of inflammation associated with Gram negative infections, for example Gram negative infection is associated with inflammatory diarrhoeas, such as those caused by Shigella sp., Salmonella sp., Campylobacter sp., Clostridium difficile and E. coli.
In one embodiment there is provided a glycodendrimer or population according to the present disclosure or a composition comprising the same for use in the treatment or prophylaxis of inflammatory bowel disease, such as Crohn's Disease and/or Ulcerative Colitis.
In one embodiment there is provided a glycodendrimer according to the present disclosure or a composition comprising the same for use in the treatment or prophylaxis of those forms of irritable bowel disease, for example associated with an excessive stimulation of Toll Like receptors by gut bacteria.
In one embodiment there is provided a glycodendrimer according to the present disclosure or a composition comprising the same for use in the treatment or prophylaxis of abnormally excessive host pro-inflammatory cytokine mediated responses in the respiratory system such as those that occur in allergy, asthma or after a bacterial and/or viral infection.
In one embodiment there is provided a glycodendrimer, population or formulation according to the present disclosure for use in the treatment or prophylaxis of inflammatory respiratory responses, such as allergy and/or asthma.
In one embodiment there is provided a glycodendrimer or population according to the present disclosure or a composition comprising the same for use in the treatment or prophylaxis of excessive scarring during wound healing, keloid formation, eczema and psoriasis.
In one embodiment there is provided a glycodendrimer or population according to the present disclosure or a composition comprising the same for use in the treatment or prophylaxis of transplants or organs or tissue, such as corneal and/or skin transplantation.
In one embodiment there is provided a glycodendrimer according to the present disclosure, for use in the treatment or prevent of undesirable angiogenesis or restenosis (for example after insertion of a stent).
In one embodiment there is provided a stent coated with a compound according to the present disclosure.
In one embodiment there is provided a glycodendrimer or population according to the present disclosure or a composition comprising the same for use in the treatment or prophylaxis of gingivitis.
In one embodiment there is provided a glycodendrimer according to the present disclosure or a composition comprising the same for use in the treatment or prophylaxis of rheumatoid arthritis or osteoporosis.
In one embodiment glycodendrimers according to the present disclosure or pharmaceutical formulations thereof are suitable for administration directly to the eye as eye drops, by deposition of a pellet in or around the eye, or by injection into any chamber within the eye, or by direct infusion through an organ, for example at a concentration ranging from 2.5 to 2,500 μg/ml.
In one embodiment there is provided a method of treatment comprising administering a therapeutically effective amount of a glycodendrimer or population according to the present disclosure or a composition comprising same to a patient in need thereof, in particular for treatment or prophylaxis of an indication described herein.
In one embodiment there is provided use of a glycodendrimer or composition comprising the same for the manufacture of a medicament for the treatment of an indication described herein.

Process Chemistry For Zero Length Amide Bond Formation

The detailed divergent chemical synthesis of polypropyletherimine dendrimers cores up to generation 3 (i.e., with 16 peripheral carboxylic acid groups) has been described in detail in [19].
Starting with an oxygen core, the dendrimer was synthesised by repetitive cycles consisting of two reductions and two Michael addition reactions. These repetitive and consecutive reactions were performed using alpha-beta-unsaturated ester and nitrile as monomers, and supported metal catalysts and metal hydrides as reagents. Esters are converted to alcohols followed by conversion of alcohols to ethers with pendant nitriles, followed by conversion of nitriles to primary amines, followed by conversion of primary amines to tertiary amines with pendant esters. The procedure described is long but simple and the yield is good.
Chromatography after the sequential synthesis of each dendrimer generation by HPLC and/or column chromatograph can be used to ensure that the single entity generation 3 polypropyletherimine is obtained as a final product. A MALDI-MS of this molecule is shown in the supplementary files attached to the following paper [19].
Synthesis of large generation polypropyletherimine dendrimers is described in [22].
A process to covalently link a biologically inactive glucosamine molecule to a biologically inactive anionic carboxylic acid terminated dendrimer molecule wherein the dendrimer core was reacted with the sugar molecule such as the glucosamine molecule in the presence of a coupling agent such as carbodiimide coupling or 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride {EDC}. The reaction is carried out in an aqueous solvent, for example water and at room temperature and without an exogenous heat source. An analogous process is described for example in WO 03/089010. In one embodiment the core is a 3, 3.5 or 4 generation dendrimer.
This process had the advantage of comprising a single synthetic step to create a covalent zero length amide bond, using water as the solvent, and it can be performed at room temperature (i.e., 18-26° C.). This process also has the advantage that it avoided the need for the use of organic solvents that are often toxic in vivo.
Furthermore, organic solvents require additional, complicated and expensive purification procedures for isolating the final product from the organic solvent. Conjugation, that is to say, covalent linkage of the components in an aqueous environment facilitates the simple and straightforward purification of the final medicinal product. This has important industrial advantages, and manufacturing advantages, and regulatory advantages for a new pharmaceutical drug.
Suitably, the dendrimers cores are covalently linked to compounds containing amino groups, for example, amine groups, for example, primary amine groups, such as amino sugars in particular glucosamine.
Typically the covalent link formed by the conjugation is stable over a period of more than 18 months, which may be important in the shelf-life of a pharmaceutical product. In one embodiment the glycodendrimer formed is lyophilised. This may further extend the shelf life of the molecule.
Thus in one aspect there is provided a process preparing a glycodendrimer according to the present invention comprising the step of conjugating a glucosamine molecule to a dendrimer core, in particular a polypropyletherimine dendrimer core, for example prepared divergently, such as a generation 3 core. In one embodiment, a covalent zero length amide bond is formed between the sugar and a carboxylic acid residue on the core. In one embodiment a coupling agent is employed selected from 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride and EDC.
In one embodiment the process employs water as the solvent. In one embodiment the reaction is carried out at less than 40° C. without the application of an external, additional energy source.
In one embodiment the glycodendrimer is purified after conjugation of the core to the sugar, for example purification may be effected by dialysis and/or by column chromatograghy.
In one embodiment the glycodendrimer obtained from said process is a monodispersion, for example with 2 glucosamine molecules attached at opposite ends of the surface of the dendrimer.
In one embodiment the disclosure relates to products obtainable from said process.
It is important to note that these anionic carboxylic acid terminated dendrimers (without glucosamine attached) have no effect on pro-inflammatory cytokines such as IL-6, IL-1 beta, TNF-alpha and MIP-1 beta even at very high doses. It is also important to note that glucosamine (on its own) also has no effect on pro-inflammatory cytokines such as IL-6, IL-1 beta, TNF-alpha and MIP-1 beta even at high doses.
Nevertheless, the present disclosure further provides use of the dendrimer cores (polypropyletherimine cores, particularly generation 3 cores), described herein in the preparation of a glycodendrimer, in particular a therapeutic glycodendrimer, in particular as described herein.
In one aspect there is provided use of glucosamine, in particular as described herein for the preparation of a glycodendrimer, in particular a therapeutic glycodendrimer, in particular as described herein.
Average as employed herein is intended to refer to a mean average or a modal average.
All citation and documents referred herein are specifically incorporated by reference.
Comprising in the context of the present invention means including.
Described above are embodiments comprising certain integers. Embodiments of the invention described above can be combined as technically appropriate. The present disclosure also extends to corresponding embodiments consisting of said integers as herein described.
All references to literature and patent documents are incorporated by reference.

EXAMPLES

The table below describes some of the compounds prepared over several years in the search for a biologically active dendrimer. Table 1 is a summary of the glycodendrimers prepared and analysed


	Biological
	Activity
	(reduction
	of pro-
GLYCODENDRIMER	inflammatory

Core	Generation	Sugar	cytokines)

Triazine	2	Glucosamine	none
		(6 equivalents used)
Triazine	2	Glucosamine	none
		(12 equivalents used)
Triazine	2	Glucosamine	none
		(120 equivalents used)
Triazine	2	Glucosamine	none
		(120 equivalents
		used at pH 5)
Triazine	3	Glucosamine	none
		50% loading
Triazine
	3	Glucosamine	none
		58% loading
Triazine
	3	Glucosamine	none
PAMAM hybrid	0.5	12.5% loading
Triazine
	3	Glucosamine	yes
PAMAM hybrid	1.5	18.75% loading	(but a
			mixture of
			multiple
			species of
			molecules
			that are not
			all closely
			related)

Example 1

Studies of Generation 3 Polypropyletherimine Carboxylic Acid Terminated Dendrimer Glucosamine

Example 1A

Synthesis

1

Despite the molecular modelling studies showing that the generation 3 polypropyletherimine carboxylic acid terminated dendrimer glucosamine (12.5% loading) would not be biologically active, we nevertheless proceeded with its chemical synthesis and its biological testing. Divergent synthesis of a generation 3 carboxylic acid terminated polypropyletherimine dendrimer has been previously described by—[19].
50 mg of a monodispersed generation 3 polypropyletherimine dendrimer (MWt 2,667) was dissolved in 0.5 ml water. 50 mg of glucosamine was dissolved in 1 mg/ml water, added to the dendrimer, and the pH adjusted to pH 5. EDC (208 mg) was dissolved in 4.1 ml of water and added to the mixture, and the pH adjusted to 5.0. The reaction was stirred for 3 h at room temperature with constant monitoring of the pH which was adjusted to pH 5.0. After 3 h, the reaction was transferred to a 2,000 MWt cut-off dialysis cassette and then dialysed for 24 h with 3 changes of water. All of the water used in the synthesis reactions and in the dialysis was endotoxin free. The dialysed reactions were lyophilised and resuspended in water at 50 mg/ml, and confirmed to be endotoxin free at <0.1 EU/ml using the limulus assay.
MALDI-MS and NMR studies showed that the monodispersed generation 3 polypropyletherimine dendrimer (with 16 peripheral carboxylic acid groups) had a loading of 2 glucosamine molecules per dendrimer (actual MWt 3,061; theoretical calculated weight 3,061). This gave a percentage glucosamine loading of 12.5%; i.e. 2 glucosamine molecules on the 16 peripheral carboxylic acid groups of this dendrimer.

Example 1B (Alternative Process)

To prepare endotoxin-free solutions and glassware, all glassware and magnetic fleas were autoclaved twice at 123° C. for 15 minutes. The synthesis was performed using sterile and endotoxin free disposable plastic tissue culture grade 50 ml universal tubes. All other disposable plastic pipettes, universals and syringes are certified endotoxin-free (i.e., endotoxin <0.01 endotoxin units (EU)/ml). Endotoxin free water for injection was used. This means that endotoxin contamination was reduced to a minimum from the very start of the partial glycosylation synthesis reaction. In order to eliminate any bacterial contamination of the pH probe used, it was first immersed in 1 N HCl solution for 15 minutes before being used, and then washed 4 times with endotoxin free water to remove any residual acid.
150 mg of the Generation 3 polypropyletherimine dendrimer was dissolved in 1.5 ml sterile endotoxin free water to give a concentration of 100 mg/ml. A magnetic flea was put into the 50 ml Falcon tube and stirred at a slow speed on a magnetic stirring plate. 150 mg of D-glucosamine hydrochloride from Sigma UK (catalogue number G4875) was dissolved in 3 ml of sterile water to give a concentration of 50 mg/ml. It was then added to the dissolved dendrimer. This was equivalent to 0.78 glucosamine molecules per peripheral carboxylic acid group on the dendrimer. The pH of the resulting solution (which is quite acidic) was readjusted to 5.0 using 1 N NaOH. Then, 334 mg of 1-ethyl-3-3-dimethylaminopropyl carboiimide hydrochloride (EDCI, Sigma UK) was dissolved in 6.7 ml sterile water to give a concentration of 50 mg/ml. This was equivalent to 1.94 EDCI molecules per peripheral carboxylic acid group on the dendrimer. The EDCI solution was then added immediately to the solution containing the dendrimer and the glucosamine The pH was readjusted to 5.0 with 1 N HCl. The pH of the reaction solution was readjusted to 5.0 by adding 1 N HCl every 15-30 minutes during the 3 hour reaction. The final volume of the reaction was about 12-12.5 ml.
For the dialysis steps that followed, all glass beakers and magnetic stir bars were autoclaved twice at 123° C. for 15 minutes. Endotoxin free water (Baxter Healthcare) was used. One of two procedures was followed. The first procedure used a Float-a-Lyzer dialysis cassette (Spectrapor) with a MWt cut-off of 1 kDa and a volume of 10 ml. In this case, the dialysis tube was rehydrated using endotoxin-free water, filled with the solution, and then dialysed (with stirring) for 1 hour in 1 L of endotoxin free water at 4° C. All subsequent dialysis was at 4° C. The water was then replaced and the dialysis continued overnight. The following day, the water was replaced and the dialysis continued for another 24 hours; i.e., a further 4 changes of water at 3.5 h intervals, and including another overnight dialysis. In total, this meant 42 hours of dialysis at 4° C. with 7 changes of water. In the second dialysis procedure, a Slide-a-lyser dialysis cassette (Pierce) with a MWt cut-off of 2 kDa and a volume of 3-12 ml was used. The dialysis cassette was rehydrated using endotoxin-free water, filled with the solution, and then dialysed (with stirring) for 1 hour in 1 L of endotoxin free water at 4° C. All subsequent dialysis was at 4° C. The water was then replaced and the dialysis continued overnight. The following day, the water was replaced and the dialysis continued for another 24 hours, with a further 4 changes of water at 3.5 hour intervals, and including another overnight dialysis. In total, this meant 42 hours of dialysis at 4° C. with 7 changes of water. The dialysate was then removed from the cassettes with a needle and syringe and filtered through 0.2 μm sterile filters and placed in pre-weighed sterile 50 ml Falcon tubes. It was then frozen for at least 1 hour at −80° C. Parafilm was placed over the mouth of the 50 ml tube that contained the frozen dendrimer glucosamine and pierced with a needle. The tube was then placed in a freeze drier (which has been pre-run for 30 min) and its contents left to lyophilize for 48 hours.
The lyophilised product was confirmed to be endotoxin free at <0.1 EU/ml using the limulus amoebocyte assay. As the dendrimer glucosamine is hygroscopic, it was stored in small airtight containers, and under argon, and at 4° C., and wrapped in aluminium foil. H-NMR and C-NMR and MALDI-MS studies showed that the Generation 3 polypropyletherimine dendrimer (with 16 peripheral carboxylic acid groups) had a loading of 2 glucosamine molecules per dendrimer. This gave a percentage glucosamine loading of 12.5%; i.e., 2 glucosamine molecules on the 16 peripheral carboxylic acid groups of this dendrimer. In addition, there was no residual small molecule contamination of the product with acrylonitrile, acrylic acid, free glucosamine or urea.

Example 2

Biological Studies With the Generation 3 Polypropyletherimine Carboxylic Acid Terminated Dendrimer Glucosamine

Example 2A

Cellular cytotoxicity was determined as follows. Peripheral blood mononuclear cells were isolated from fresh human blood by density gradient centrifugation and re-suspended in growth medium (RPMI 1640, 20 mM L-glutamine, penicillin [250 IU/ml], streptomycin [250 μg/m1] and 10% endotoxin free human serum). They were allowed to adhere to plastic tissue culture plates for 1 h. The plates were washed, the adherent monocytes scraped with a cell scraper, and the cell density adjusted to 10⁶cells/ml. 200 μL of these monocytes were plated in a 96 well plate at a density of 10⁶cells/ml. The generation 3 polypropyletherimine dendrimer (0 to 400 μg/ml) was added to monocytes and incubated for 24 h. Cell viability was assessed using the MTT assay. No cytotoxic effect of the generation 3 polypropyletherimine carboxylic acid terminated dendrimer was found up to the highest concentration tested. The generation 3 polypropyletherimine dendrimer glucosamine (0 to 400 μL/ml) was then added to monocytes and incubated for 24 h. Cell viability was assessed using the MTT assay. No cytotoxic effect of the generation 3 polypropyletherimine carboxylic acid terminated dendrimer glucosamine was found up to the highest concentration tested (FIG. 7).

Example 2B

The Ability of the Generation 3 Polypropyletherimine Dendrimer Glucosamine to Reduce Pro-Inflammatory Cytokine Production was Determined in a Human Monocyte/Macrophage Based Assay With LPS Being Used to Stimulate the Release of Pro-Inflammatory Cytokines

1 ml aliquots of human monocytes (10⁶cells/ml) were transferred to a 24-well tissue culture plate and incubated for 30 min at 37° C. To these adherent monocytes, endotoxin free (i.e., <0.01 EU/ml) generation 3 polypropyletherimine carboxylic acid terminated dendrimer glucosamine was added at concentrations from 50 to 200 μg/ml and incubated for 1 h at 37° C. LPS (Salmonella Minnesota, Sigma. Catalogue number L9764) was added at 25 ng/ml. Positive controls were cells treated with LPS only, and the negative controls were untreated cells, or cells incubated with the dendrimer only. The cells were then maintained at 37° C. with 5% CO₂for 3 h. Media was then removed, cells lysed in 500 μL of Tri-reagent (Sigma) and RNA extracted. Reverse transcription was performed using a Qiagen RT kit. Aliquots of cDNA were then subjected to quantitative real-time PCR for a panel of cytokines. A large reduction in the synthesis of the pro-inflammatory cytokines IL-6, TNF-alpha, IL-8, and MIP-1 beta was seen in the presence of the generation 3 anionic polypropyletherimine carboxylic acid terminated dendrimer glucosamine at a concentration of 100 μg/ml. In addition, no change was seen in the anti-inflammatory cytokines IL-10 and interferon-beta (FIGS. 7 and 8). This was a very surprising and unexpected biological result.

Example 2C

Detailed Biological Studies with the Generation 3 Polypropyletherimine Carboxylic Acid Terminated Dendrimer Glucosamine

The reduction in the production of the pro-inflammatory cytokines IL-6, TNF-alpha, IL-8 and MIP-1 beta seen with generation 3 polypropyletherimine carboxylic acid terminated dendrimer glucosamine at a dose of 100 μg/ml with Salmonella sp. LPS was a surprising result because all of our molecular modelling studies had suggested that the generation 3 polypropyletherimine dendrimer glucosamine (with only 16 carboxylic acids available for the conjugation to glucosamine) would:—(1) be too small a molecule; (2) it would not have the correct physic-chemical characteristics to act as an effective antagonist of the MD2-TLR4-LPS mediated pro-inflammatory cytokine response.
To further verify the validity of the biological results obtained above with the generation 3 polypropyletherimine carboxylic acid terminated dendrimer glucosamine, additional biological experiments were performed.

Example 2D

Assay for Inhibition of Pro-Inflammatory Cytokine Production by Generation 3 Polypropyletherimine Carboxylic Acid Terminated Dendrimer Glucosamine After Challenge With Shigella Sp. Wild Type LPS And Molecularly Modified Waal Mutant Shigella Sp. LPS

Wild type M90 and the Shigella mutant (waaL—which has no O-antigen glucosylation pattern—see FIG. 9 and also [25]) were propagated and their LPS extracted by phenol extraction. The LPS derived from:—(1) wild-type Shigella M90; (2) waaL, were added at 25 ng/ml.
Treatment of human monocytes with LPS isolated from wild type and waaL Shigella mutants induced the expression of the pro-inflammatory cytokines IL-6, TNF-alpha, IL-8 and MIP-1 beta at similar levels. Pre-treatment of monocytes with 25 to 100 μg/ml of generation 3 anionic polypropyletherimine carboxylic acid terminated dendrimer glucosamine resulted in a dose dependant reduction of all of these pro-inflammatory cytokines when Shigella wild type LPS was used (FIG. 10), and also when Shigella waaL mutant LPS was also used (FIG. 10). A modest reduction of the pro-inflammatory cytokines was seen with 25 μg/ml of generation 3 polypropyletherimine carboxylic acid terminated dendrimer glucosamine with a maximal effect seen at a dose of 100 μg/ml of generation 3 anionic polypropyletherimine carboxylic acid terminated dendrimer glucosamine.

Example 2E

Assay for Inhibition of Pro-Inflammatory Cytokine Production by G3.5 Polyamidoamine Dendrimer Glucosamine and G3 Polypropyletherimine Dendrimer Glucosamine After Challenge of Rabbits Infected With Wild Type Shigella Sp. Infection

Surgery to create ileal loop sacs in rabbits was performed as described previously [26]. This rabbit model has proven invaluable for studies of mucosal inflammation and bacterial invasion in infectious diarrheas. Shigellosis (and the typhoid fever of salmonella) lead to inflammatory changes in the epithelium associated lymphoid follicles; i.e., Peyer's patches [26,27]. The localised but excessive IL-6 and TNF-alpha mediated pro-inflammatory cytokine response that follows leads to the destruction of the intestinal epithelium because:—(1) the organism multiples in the lumen of the isolated ileal loops; (2) a severe host mediated pro-inflammatory response occurs; (3) the mucosal barrier is damaged; and (4) bacterial invasion occurs through the gut associated lymphoid tissues (i.e., Peyer's patches). This is associated with an infiltration of:—(a) blood derived monocytes that differentiate into macrophages; and (b) neutrophils. The inflammatory changes in this rabbit based ileal loop model depend directly upon the presence of shigella LPS and the production of IL-6 and TNF-alpha by the large numbers of incoming blood monocytes.
For these experiments, wild-type M90 Shigella flexneri bacteria were grown in broth, harvested whilst still in the exponential phase of growth, and diluted to give a concentration of 2×10⁷bacteria per ml. The rabbit ileal loops containing Peyer's patches were treated with 2.5 mg of generation 3.5 polyamidoamine (PAMAM) dendrimer glucosamine and the control loop was treated with 2.5 mg of generation 3.5 polyamidoamine (PAMAM) dendrimer. These molecules were administered in a volume of 1 ml of water. 10⁷M90 Shigella flexneri bacteria were then injected into each ileal loop. The abdomen was closed and the rabbits left for 16 h. The rabbits were then killed and the ileal loops and Peyer's patches sampled. Tissue was immediately immersed in 2 ml of TriReagent, homogenised for 1 min using a Polytron homogenizer and the RNA extracted for quantitative real-time RT-PCR based studies of pro-inflammatory cytokines.
No adverse reaction were seen when dendrimer glucosamine was administered into the ileal loops. In these experiments, and using wild type Shigella flexneri (M9OT strain; 10⁷organisms/loop), it was shown that:—(1) Neither the dendrimer nor the PAMAM dendrimer glucosamine had an anti-microbial effect on the Shigella flexneri when administered into the ileal loops; (2) A significant and therapeutically beneficial effect could be achieved after the oral administration of dendrimer glucosamine into the gut lumen; (3) No clinical toxicity was seen; (4) Functional tissue injury was reduced by PAMAM dendrimer glucosamine as determined by a 90% reduction in the volume of bloody diarrhoea that occurs during a shigella infection; (5) Histo-pathological studies showed that infected animals receiving dendrimer only have a marked tissue pro-inflammatory cell infiltrate in the gut wall and gut lumen, edema of the lymphoid follicles (i.e., Peyer's patches), extensive destruction of the epithelium associated with the lymphoid follicle, and inflammation, hemorrhagic infiltration, dilatation, shortening and destruction of the villi between the lymphoid follicles (i.e., Peyer's patches). In contrast, the histo-pathological findings were quite different in the infected animals treated by the oral administration of dendrimer glucosamine into the gut lumen in that there were minimal morphological changes in the mucosal villi and Peyer's patch follicles, and the tissue based inflammatory cell infiltrate present did not cause epithelium rupture ; (6) There was a large reduction in pro-inflammatory cytokine production as demonstrated by a 1,000-fold reduction in IL-6 production, a 100-fold reduction in IL-8 production, and a 100-fold reduction in TNF-alpha production. Importantly, for the anti-inflammatory cytokine IL-10, there was no difference. For the dendritic cell maturation mediator—Interferon-beta—there was also no difference. For the epithelial cell anti-microbial peptide β-defensin, there was no difference. These animal model based results showed that dendrimer glucosamine can substantially alter the course of a gut infection even when an antibiotic is not co-administered during the course of these experiments.
The above experiment was repeated with a G3 polypropyletherimine dendrimer glucosamine according to the present invention.

Example 2F

Assay for Inhibition of pro-Inflammatory Cytokine Production by Generation 3 Polypropyletherimine Carboxylic Acid Terminated Dendrimer Glucosamine After Challenge With LPS, Live E. Coli Bacteria, Live Klebsiella Aeruginosa Bacteria, Live S. Aureus Bacteria, Live E. Faecalis Bacteria, and Live Pseudomonas Aerugenosa Bacteria

1 ml aliquots of human monocytes (10⁶cells/nil) were transferred to a 24-well tissue culture plate and incubated for 30 min at 37° C. To these adherent monocytes, endotoxin free dendrimer glucosamine was added at concentrations from 50 to 200 μg/ml and incubated for 1 h at 37° C. Live Escherichia coli, Klebsiella aeruginosa, Staphylococcus aureus, Escherichia faecalis, and Pseudomonas aerugenosa from overnight bacterial cultures were added to separate plates of monocytes at a multiplicity of infection of 10 infectious bacteria per monocyte (total volume 50 μL) and centrifuged at 780 g for 7 min to maximise the contact between the bacteria and the monocytes. The cells were then maintained at 37° C. with 5% CO₂for 1 h. Gentamicin (100 μg/m1) was then added and the tissue culture plate incubated for an additional 2 h. Media was then removed, cells lysed in 500 μL Tri-reagent (Sigma), and the RNA extracted. Reverse transcription was performed using a Qiagen RT kit. Aliquots of cDNA were then subjected to quantitative real-time mRNA PCR for pro-inflammatory cytokines.
A large reduction in the synthesis of the pro-inflammatory cytokines IL-6 (FIG. 12), TNF-alpha (FIG. 13) and MIP-1 beta (FIG. 14) was seen in the presence of the generation 3 polypropyletherimine carboxylic acid terminated dendrimer glucosamine (12.5% loading) molecule at a concentration of 100 μg/ml.
FIG. 1: Illustration showing competition for cell surface Toll-like receptor 4 (TLR4) between the agonist (lipopolysaccharide [LPS])) and the antagonist (dendrimer glucosamine). MD2 is a protein and R1, R2, R3, and R4 are acyl chains.
FIG. 2: shows a diagrammatic representation of a PAMAM glucosamine dendrimer.
FIG. 3: Generation 3 anionic carboxylic acid terminated (i.e., 16 peripheral carboxylic acid groups) polypropyletherimine dendrimer core. The entire and symmetrical dendrimer is shown in 2-dimensions. This dendrimer does not have internal cavities. It is therefore not suitable for acting as a drug delivery dendrimer.
FIG. 4: Generation 3 anionic carboxylic acid terminated (i.e., 16 peripheral carboxylic acid groups) polypropyletherimine dendrimer glucosamine with a 12.5% surface loading of glucosamine (i.e., 2 glucosamine molecules) with a zero length amide bond between the dendrimer and the glucosamine The glucosamine molecules are evenly spaced on the surface of this symmetrical dendrimer as illustrated by each of the black stars. Each of the arcs (n=2) represents the eight carboxylic acid groups to one of which is covalently attached a glucosamine molecule. This analytical chemistry observation is consistent with higher occupied molecular orbital and lowest occupied molecular orbital calculations that were performed using the frontier molecular orbital theory. In the case of a generation 3 anionic carboxylic acid terminated (i.e., 16 peripheral carboxylic acid groups) polypropyletherimine dendrimer, the incremental addition of each glucosamine proceeds in a energy favourable manner until 2 glucosamine molecules have been attached to 2 of the 16 peripheral carboxylic acid groups available. Thereafter, the higher occupied molecular orbital energy values rapidly becomes less favourable to the addition of any further glucosamine molecules. This suggests that the divergent approach to the synthesis of dendrimer glucosamine leads to the favourable addition of 2 glucosamine molecules on the 16 carboxylic acid groups of a generation 3 anionic carboxylic acid terminated polypropyletherimine dendrimer. This equates to one glucosamine molecule per eight peripheral carboxylic acid groups.
FIG. 5: Generation 3 anionic carboxylic acid terminated polypropyletherimine dendrimer glucosamine. This figure shows its overall molecular surface. This dendrimer does not have internal cavities. It is therefore not suitable for drug delivery purposes.
FIG. 6: Generation 3 anionic carboxylic acid terminated polypropyletherimine dendrimer glucosamine This dendrimer glucosamine does not have internal cavities and is therefore not suitable for drug delivery purposes. This figure shows modeling of its hydrophilic surfaces.
FIG. 7: Cellular cytotoxicity was determined by an MTT assay performed on 10⁵human monocytes in 96 well plates using 0 to 400 μg/ml of an endotoxin free generation 3 polypropyletherimine anionic carboxylic acid terminated dendrimer glucosamine No cytotoxic effect was observed. The biological effect of generation 3 polypropyletherimine anionic carboxylic acid terminated dendrimer glucosamine was determined in 24 well plates using 10⁶peripheral blood mononuclear cells pretreated with 12.5 to 100 μg/ml endotoxin free dendrimer glucosamine for 1 h followed by challenge with 25 ng/ml Salmonella LPS. After 3 h, RNA was extracted and real-time RT PCR performed. When compared with the LPS control, generation 3 polypropyletherimine anionic carboxylic acid terminated dendrimer glucosamine lead to the following reductions in pro-inflammatory cytokines:—an 75-fold reduction in IL-6, a 390-fold reduction in TNF-alpha, a 75-fold reduction in IL-8, and a 165-fold reduction in MIP-1 beta at 100 μg/ml. In contrast, there was no change in the anti-inflammatory cytokines IL-10 and interferon-beta.
FIG. 8: Cellular cytotoxicity was determined by an MTT assay performed on 10⁵human monocytes in 96 well plates using 0 to 400 μg/ml of an endotoxin free generation 3 polypropyletherimine anionic carboxylic acid terminated dendrimer glucosamine No cytotoxic effect was observed. The biological effect of generation 3 polypropyletherimine anionic carboxylic acid terminated dendrimer glucosamine was determined in 24 well plates using 10⁶monocytes pretreated with 50 to 200 μg/ml endotoxin free dendrimer glucosamine for 1 h followed by challenge with 25 ng/ml Salmonella LPS. After 3 h, RNA was extracted and real-time RT PCR performed. When compared with the LPS control, generation 3 polypropyletherimine anionic carboxylic acid terminated dendrimer glucosamine lead to the following reductions in pro-inflammatory cytokines:—an 300-fold reduction in IL-6, a 135-fold reduction in TNF-alpha, a 5-fold reduction in IL-8, and a 100-fold reduction in MIP-1 beta at 100 μg/ml. In contrast, there was no change in the anti-inflammatory cytokines IL-10 and interferon-beta.
FIG. 9: Schematic representation of the possible truncation mutants of Shigella LPS. M90 is the wild type Shigella flexneri. gtrA is a mutant with reduced glucosylation. cld (chain length determinant) and dB are O-antigen truncated mutants. waal mutants only have the Lipid A and core sugars without the O-antigen.
FIG. 10: The biological effect of generation 3 polypropyletherimine anionic carboxylic acid terminated dendrimer glucosamine was determined in 24 well plates using 10⁶human monocytes pretreated with 25 to 200 μg/ml endotoxin free dendrimer glucosamine for 1 h followed by challenge with 25 ng/ml Shigella LPS. After 3 h, RNA was extracted and real-time RT PCR performed. When compared with the LPS control, generation 3 polypropyletherimine anionic carboxylic acid terminated dendrimer glucosamine lead to the following reductions in pro-inflammatory cytokines:—an 30-fold reduction in IL-6, a 4-fold reduction in TNF-alpha, a 15-fold reduction in IL-8, and a 6-fold reduction in MIP-1 beta at 100 μg/ml. In contrast, there was no change in the anti-inflammatory cytokines IL-10 and interferon-beta.
FIG. 11: The biological effect of generation 3 polypropyletherimine anionic carboxylic acid terminated dendrimer glucosamine was determined in 24 well plates using 10⁶human monocytes pretreated with 25 to 200 μg/ml endotoxin free dendrimer glucosamine for 1 h followed by challenge with 25 ng/ml Shigella waaL LPS. After 3 h, RNA was extracted and real-time RT PCR performed. When compared with the LPS control, generation 3 polypropyletherimine anionic carboxylic acid terminated dendrimer glucosamine lead to the following reductions in pro-inflammatory cytokines:—a 12-fold reduction in IL-6, a 3-fold reduction in TNF-alpha, a 4-fold reduction in IL-8, and a 5-fold reduction in MIP-1 beta at 200 μg/ml. In contrast, there was no change in the anti-inflammatory cytokines IL-10 and interferon-beta.
FIG. 12: The biological effect of generation 3 polypropyletherimine anionic carboxylic acid terminated dendrimer glucosamine was determined in 24 well plates using 10⁶human monocytes pretreated with 12.5 to 100 μg/m1 endotoxin free dendrimer glucosamine for 1 h followed by challenge with:—(1) 25 ng/ml Salmonella LPS; (2) live E. coli bacteria (multiplicity of infection (MOI)=10); (3) live Pseudomonas aeruginosa bacteria (MOI=10); (4) live Klebsiella pneumonia bacteria (MOI=10); (5) live S. aureus bacteria (MOI=10); (6) live E. faecalis bacteria (MOI =10). After a 1 h incubation, gentamycin (100 μg/ml) was added to the monocyte cultures containing bacteria and the incubation was then continued for another 2 h, making a total of a 3 hour incubation. The RNA was then extracted and real-time RT PCR performed. In the case of every single stimulant used, generation 3 polypropyletherimine anionic carboxylic acid terminated dendrimer glucosamine lead to a significant reduction in the pro-inflammatory cytokines IL-6, TNF-alpha, and IL-8.
This figure summarises the results for IL-6. They show the following reductions:—(1) Salmonella LPS—a 925-fold reduction at 100 μg/ml; (2) live E. coli bacteria—a 30-fold reduction at 100 μg/ml; (3) live Pseudomonas aerugenosa bacteria—a 23-fold reduction at 100 μg/ml; (4) live Klebsiella pneumonia bacteria—a 48-fold reduction at 200 μg/ml; (5) live S. aureus bacteria—a 17-fold reduction at 100 μg/ml; (6) live E. faecalis bacteria—a 60-fold reduction at 200 μg/ml.
FIG. 13: The biological effect of generation 3 polypropyletherimine anionic carboxylic acid terminated dendrimer glucosamine was determined in 24 well plates using 10⁶human monocytes pretreated with 12.5 to 100 μg/ml endotoxin free dendrimer glucosamine for 1 h followed by challenge with:—(1) 25 μg/ml Salmonella LPS; (2) live E. coli bacteria (multiplicity of infection (MOI)=10); (3) live Pseudomonas aeruginosa bacteria (MOI=10); (4) live Klebsiella pneumonia bacteria (MOI=10); (5) live S. aureus bacteria (MOI=10); (6) live E. faecalis bacteria (MOI=10). After a 1 h incubation, gentamycin (100 μg/ml) was added to the monocyte cultures containing bacteria and the incubation was then continued for another 2 h, making a total of a 3 hour incubation. The RNA was then extracted and real-time RT PCR performed. In the case of every single stimulant used, generation 3 polypropyletherimine anionic carboxylic acid terminated dendrimer glucosamine lead to a significant reduction in the pro-inflammatory cytokines IL-6, TNF-alpha, and IL-8.
This figure summarises the results for TNF-alpha. They show the following reductions:—(1) Salmonella LPS—an 20-fold reduction at 100 μg/ml; (2) live E. coli bacteria—a 6-fold reduction at 100 μg/ml; (3) live Pseudomonas aeruginosa bacteria—a 3-fold reduction at 100 μg/ml; (4) live Klebsiella pneumonia bacteria a 12-fold reduction at 200 μg/ml; (5) live S. aureus bacteria—a 10-fold reduction at 100 μg/ml; (6) live E. faecalis bacteria—a 45-fold reduction at 200 μg/ml.
FIG. 14: The biological effect of generation 3 polypropyletherimine anionic carboxylic acid terminated dendrimer glucosamine was determined in 24 well plates using 10⁶human monocytes pretreated with 12.5 to 100 μg/m1 endotoxin free dendrimer glucosamine for 1 h followed by challenge with:—(1) 25 ng/ml Salmonella LPS; (2) live E. coli bacteria (multiplicity of infection (MOI)=10); (3) live Pseudomonas aeruginosa bacteria (MOI=10); (4) live Klebsiella pneumonia bacteria (MOI=10); (5) live S. aureus bacteria (MOI=10); (6) live E. faecalis bacteria (MOI=10). After a 1 h incubation, gentamycin (100 μg/ml) was added to the monocyte cultures containing bacteria and the incubation was then continued for another 2 h, making a total of a 3 hour incubation. The RNA was then extracted and real-time RT PCR performed. In the case of every single stimulant used, generation 3 polypropyletherimine anionic carboxylic acid terminated dendrimer glucosamine lead to a significant reduction in the pro-inflammatory cytokines IL-6, TNF-alpha, and IL-8.
This figure summarises the results for MIP-1 beta. They show the following reductions:—(1) Salmonella LPS—a 70-fold reduction at 100 μg/ml; (2) live E. coli bacteria—a 5-fold reduction at 300 μg/ml; (3) live Pseudomonas aerugenosa bacteria—a 3-fold reduction at 100 μg/ml; (4) live Klebsiella pneumonia bacteria—a 30-fold reduction at 200 μg/ml; (5) live S. aureus bacteria—a 5-fold reduction at 100 μg/ml; (6) live E. faecalis bacteria—a 35-fold reduction at 200 μg/ml.
FIG. 15: Shows the H-NMR spectrum for the polypropyletherimine core with 16 terminal carboxylic acids.
FIG. 16: Shows the 2-dimensional H-COSY spectrum for the polypropyletherimine core with 16 terminal carboxylic acids.
FIG. 17: Shows the ¹³C-NMR spectrum for the polypropyletherimine core with 16 terminal carboxylic acids.
FIG. 18: Shows the Distortionless Enhancement by Polarization Transfer 135 ¹³CNMR spectrum for the polypropyletherimine core with 16 terminal carboxylic acids.
FIG. 19: Shows the MALDI mass spectrum for the polypropyletherimine core with 16 terminal carboxylic acids.
FIG. 20: Shows the HPLC charged aerosol detection trace for the polypropyletherimine core with 16 terminal carboxylic acids.
FIG. 21: Shows a diagrammatic representation of PETIM conjugation to glucosamine
FIG. 22 a: Shows the H-NMR spectrum for the polypropyletherimine dendrimer glucosamine (with 16 terminal carboxylic acids).
FIG. 22 b: Shows the ¹³C-NMR spectrum for the polypropyletherimine dendrimer glucosamine (with 16 terminal carboxylic acids).
FIG. 23: Shows the HPLC-UV trace for the polypropyletherimine dendrimer glucosamine (with 16 terminal carboxylic acids).
FIG. 24: Show polypropyletherimine-glucosamine is not cytotoxic to primary human monocytes.
FIG. 25: Shows high purity (95%) polypropyletherimine-glucosamine tested using human monocytes and shigella LPS was bioactive at 50 μg/ml.
FIG. 26: Shows polypropyletherimine-glucosamine tested using human monocytes and infectious E. coli bacteria was bioactive at 100 μg/ml.
FIG. 27: Shows polypropyletherimine-glucosamine after storage at 37° C. & 100% humidity in a sealed vial (under argon and moisture free) for 42 days was still bioactive at 100 μg/ml when tested using human monocytes and salmonella LPS.
FIG. 28: Shows Polypropyletherimine-Glucosamine does not have Antibacterial Properties

Statement as to US Government Sponsored Research:

This invention was made, in part, with US Government funds from the National Institutes of Health. The US Government has certain rights in the invention.
1) Park B S, Song D H, Kim H M, Choi B S, Lee H, Lee J O. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009; 458: 1191-1195
2) Viriyakosol S, Tobias P S, Kitchens R L, Kirkland T N. MD2 binds to bacterial lipopolysaccharide. J. Biological Chemistry 2001; 276(41): 38,044-38,051
3) Meng J et al, MD2 residues TYR 42, ARG 69, ASP 122 and LEU 125 provide species specificity for Lipid IVA. J Biol Chem. DOI: M110.134668
4) Meng J, Lien E, Golenbock D T. MD2 mediated ionic interactions between Lipid A and TLR4 are essential for receptor activation. J Biol Chem. 2009; 285: 8695-8702
5) Atala A, Irvine D J, Moses M, Shaunak S. Wound healing versus regeneration: Role of the tissue environment in regenerative medicine. MRS Bulletin August 2010; 35: 597-606
6) Hourani R & Kakkar A. Advances in the elegance of chemistry in designing dendrimers. Macromol. Rapid Commun. 2010 ; 31: 947-974
7) Tomalia D A, Naylor A M, Goddard III W A. (1990) Starburst dendrimers: molecular level control of size, shape, surface chemistry, topology and flexibility from atoms to macroscopic matter. Angewandte Chemie-International Edition, 29, 138-175
8) Shaunak S, Thomas S, Gianasi E, Godwin A, Jones E, Teo I, Mireskandari K, Luthert P, Duncan R, Patterson S, Khaw P & Brocchini S. Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nature Biotechnology 2004; 22: 977-985
9) Vogte F, Richardt G, Werner N. Dendrimer chemistry—concepts, synthesis, properties and applications. 2009. Publisher Wiley. Chapter 1, pages 1-22
10) Menjoge A R, Kannan R M, Tomalia D A, Dendrimer based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discovery Today 2010; 15(5-6): 171-185
11) Malik N, Wiwattanapatapee R, Klopsch R, Lorenz K, Frey H, Weener J W, Meijer E W, Paulus W & Duncan R. (2000) Dendrimers: Relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 1251-labelled polyamidoamine dendrimers in vivo. Journal of Controlled Release 65, 133-148
12) Ashton P R, Boyd S E, Brown C L, Nepogodiev S A, Meijer E W, Peerlings H W I, Stoddart J F. Synthesis of glycodendrimers by modification of polypropylene imine) dendrimers. Chem. Eur. J. 1997; 3(6): 974-984
13) Turnbull W B & Stoddard J F. Design and synthesis of glycodendrimers. Reviews in Molecular Biotechnology. 2002; 90: 231-255
14) Vogte F, Richardt G, Werner N. Dendrimer chemistry—concepts, synthesis, properties and applications. 2009 Publisher Wiley. Chapter 8: Special properties and potential applications. Pages 289-324
15) Barata T S, Shaunak S, Teo I, Zloh M, Brocchini S. Structural studies of biologically active glycosylated polyamidoamine (PAMAM) dendrimers. J Mol Model. 2010 Epub ahead of print: doi 10.1007/s00894-010-0907-1;
16) Barata TS, Brocchini S, Teo I, Shaunak S, Zloh M. From sequence to 3D structure of hyperbranched molecules: application to surface modified PAMAM dendrimers. J Mol Model. 2011 Epub ahead of print: doi 10.1007/s00894-011-0966-y;
17) Barata TS, Teo I, Brocchini S, Zloh M, Shaunak S. Partially glycosylated dendrimers block MD-2 and prevent TLR4-MD-2-LPS complex mediated cytokine responses 2011 {In press in PLOS Computational Biology};
18) Shaunak S, Thomas S, Gianasi E, Godwin A, Jones E, Teo I, Mireskandari K, Luthert P, Duncan R, Patterson S, Khaw P & Brocchini S. Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nature Biotechnology 2004; 22: 977-985
18a) Barata T S, Teo I, Brocchini S, Zloh M, Shaunak S. Partially glycosylated dendrimers block MD-2 and prevent TLR4-MD-2-LPS complex mediated cytokine responses. PLoS Comput Biol 2011;7(6): e1002095. doi:10.1371/journal.pcbi.1002095
19) Krishna T R & Jayaraman N. Synthesis of poly(propyl ether imine) dendrimers and evaluation of their cytotoxic properties. J. Organic Chemistry 2003; 68(25): 9,694-9,704
20) Krishna TR, Jain S, Tatu US, Jayaraman N. Synthesis and biological evaluation of 3-amino-propanol-1-ol based poly(ether imine) dendrimers. Tetrahedron 2005; 61: 4281-4288.
21) Jana C, Jayamurugan G, Ganapathy R, Maiti P K, Jayaraman N, Sood A K. Structure of poly(propyl ether imine) dendrimer from fully atomic molecular dynamics simulation and by small angle x-ray scattering. J. Chemical Physics 2006; 124: 204719
22) Jayamurugan G, Jayaraman N. Synthesis of large generation poly(propyl ether imine) dendrimers. Tetrahedron 2006; 62: 9582-9588
23) Zuany-Amorim C, Hastewell J, Walker C. Toll-like receptors as potential therapeutic targets for multiple diseases. Nature Reviews Drug Discovery 2002; 1: 797-807
24) Kagan J C, Su T, Horng T, Chow A, Akira S, Medzhitov R. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nature Immunology 2008; 9: 361-368
25) West N P, Sansonetti P, Mounier J, Exley R M, Parsot C, Guadagnini S, Prevost M C, Prochnicka-Chalufour A, Delepierre M, Tanguy M, Tang C M. Optimization of virulence functions through glucosylation of Shigella LPS. Science 2005; 307: 1313-1317
26) Perdomo O J, Cavaillon J M, Huerre M, Ohayon H, Gounon P, Sansonetti P J. Acute inflammation causes epithelial invasion and mucosal destruction in experimental shigellosis. J Exp Med. 1994; 180: 1307-1319
27) Sansonetti P J, Arondel J, Cavaillon J M, Huerre S M. Role of interleukin-1 in the pathogenesis of experimental shigellosis. J Clinical Investigation 1995; 96: 884-892

Claims

1. A glycodendrimer comprising:

a) a non-toxic dendrimer polypropyletherimine core supporting 16 terminal carboxylic acid groups, and

b) conjungated to said core 2, 3, 4 or 5 glucosamine molecules,

wherein each glucosamine is linked directly through a zero length amide bond with a residue of a terminal carboxylic acid group.

2. A glycodendrimer according to claim 1 comprising 2, 3 or 4 glucosamine molecules.

3. A glycodendrimer according to claim 1 wherein the glycodendrimer is a generational dendrimer core.

4. A glycodendrimer according to claim 3, wherein the dendrimer core is a generation 3.

5. A glycodendrimer according to claim 1, wherein the dendrimer core has a central atom which is oxygen.

6. A glycodendrimer according to claim 1, wherein the dendrimer core has a central atom which is nitrogen.

7. A population of glycodendrimers wherein the average properties of the population are as defined in claim 1.

8. A pharmaceutical formulation comprising a glycodendrimer as defined in claim 1 or a population of glycodendrimers wherein the average properties of the population are as defined in claim 1 and a pharmaceutically acceptable excipient.

9. A formulation according to claim 8, which is formulated for topical administration, for infusion or direct injection, or for oral administration.

10. (canceled)

11. (canceled)

12. A formulation according to claim 8, wherein one dose contains in range of 10 μg to 1 g of glycodendrimer as defined in claim 1 or a population of glycodendrimers wherein the average properties of the population are as defined in claim 1.

13-23. (canceled)

24. A method of treatment, comprising administering to a patient in need thereof a therapeutically effective amount of a glycodendrimer according to claim 1, a population of glycodendrimers wherein the average properties of the population are as defined in claim 1, or a formulation comprising the glycodendrimer or the population.

25. A method according to claim 24, wherein the glycodendrimer, population or formulation is administered for the treatment of a disease or condition that is associated with an excessive pro-inflammatory cytokine response in the patient.

26. A method according to claim 25, wherein the response is mediated by increased levels of one or more cytokines selected from the group consisting of IL-6, TNF-α, IL-8, IL-1 β, and MIP-1 α and β.

27. A method according to claim 25, wherein the pro-inflammatory cytokine response is associated with a Gram negative and/or a Gram positive bacterial infection.

28. A method according to claim 27 wherein the Gram negative infection is associated with diarrhoea.

29. A method according to claim 27, wherein the infection is caused by Eschericia coli, Klebsiella aeruginosa, Staphylococcus aureus, Eschericia faecalis, and/or Pseudomonas aerugenos.

30. A method according to claim 25, wherein the pro-inflammatory cytokine response is caused by inflammatory bowel disease.

31. A method according to claim 30, wherein the inflammatory bowel disease is associated with an excessive stimulation of Toll Like receptors by gut bacteria.

32. A method according to claim 25, wherein the pro-inflammatory cytokine response is caused by an inflammatory respiratory response.

33. A method according to claim 24, wherein the glycodendrimer, population or formulation is administered in the treatment or prophylaxis of excessive scarring during wound healing, keloid formation, eczema. or psoriasis.

34. A method according to claim 33, wherein the excessive scarring happens during wound healing is following a transplant.

35. A method according to claim 25, wherein the pro-inflammatory cytokine response is due to gingivitis.